Document:

<PAGE>
                                                                    Exhibit 10.2

                           INFORMATION RESOURCES, INC.
                   AMENDED AND RESTATED SECURITY AGREEMENT

      This Amended and Restated Security Agreement (the "Agreement") is dated as
of October 16, 2001, between Information Resources, Inc. a Delaware corporation,
with its mailing address at 150 N. Clinton Street, Chicago, Illinois 60606 (the
"Company"), and Harris Trust and Savings Bank, an Illinois banking corporation
("Harris Bank"), with its mailing address at 111 West Monroe Street, Chicago,
Illinois 60603 acting as agent hereunder for the Lenders hereinafter identified
and defined (said Harris Bank acting as such agent and any successor or
successors to said Harris Bank acting in such capacity being hereinafter
referred to as the "Agent");

                             PRELIMINARY STATEMENT:

      A.    The Company, Harris Bank individually and as agent, certain other
financial institutions have entered into a Credit Agreement dated as October 31,
1997, as amended and currently in effect (such Credit Agreement, as so amended,
as the same may be further amended, modified or restated from time to time being
hereinafter referred to as the "Credit Agreement"), pursuant to which such
lenders (those lenders which are now or which from time to time hereafter become
party to the Credit Agreement being hereinafter referred to collectively as the
"Lenders" and individually as a "Lender") have agreed, subject to certain terms
and conditions, to extend a revolving credit facility to the Company;

      B.    The Company may from time to time enter into one or more interest
rate exchange, cap, collar, floor or other agreements with one or more of the
Lenders party to the Credit Agreement or their affiliates for the purpose of
hedging or otherwise protecting the Company against changes in interest rates on
the Notes (the liability of the Company in respect of such agreements with such
Lenders or their affiliates being hereinafter referred to as the "Hedging
Liability"); and

      C.    Indebtedness, obligations, and liabilities of the Company under the
Credit Agreement, and the related notes and collateral documents, together with
the Hedging Liability, are currently secured by that certain Security Agreement
dated as of October 18, 2000, between the Company and Harris Bank, and the
personal property of the Company described therein (the "Prior Security
Agreement").

      D.    Effective July 1, 2001, certain states and other jurisdictions
adopted revisions to Article 9 of the Uniform Commercial Code (the "Revised
UCC"). The Revised UCC, among other things, expands the scope of personal
property and transactions covered by such law.

      E.    The Company and the Agent, on behalf of the Lenders, agree to
supplement the Security Agreement by including as part of the Collateral certain
additional personal property and transactions now covered by the Revised UCC and
conforming certain terms used herein to those used in the Revised UCC, all as
described herein.
<PAGE>
      F.    As a condition to extending credit or otherwise making financial
accommodations available to or for the account of the Company (whether under the
Credit Agreement or otherwise), the Lenders require, among other things, that
the Company grant the Agent, on behalf of the Lenders, a security interest in
the Company's personal property described herein subject to the terms and
conditions hereof and, in connection therewith, that the Prior Security
Agreement be amended and restated in its entirety to read as set forth in this
Agreement (this Agreement and the various other instruments and documents
entered into in connection herewith being hereinafter referred to as the
"Collateral Documents").

      NOW, THEREFORE, for and in consideration of the execution and delivery by
the Lenders of the Third Amendment to Credit Agreement dated as of even date
herewith, and other good and valuable consideration, receipt whereof is hereby
acknowledged, the parties hereto hereby agree as follows:

      Section 1.  Grant of Security Interest in the Collateral; Obligations
Secured.

      (a)   The Company hereby grants to the Agent for the benefit of the
Lenders (and, in the case of Hedging Liability, their affiliates) a security
interest in and right of set-off against, and acknowledges and agrees that the
Agent has and shall continue to have for the benefit of the Lenders (and, in the
case of Hedging Liability, their affiliates) a continuing security interest in
and right of set-off against, any and all right, title and interest, whether now
owned or existing or hereafter created, acquired or arising, in and to all
personal property of the Company including all of the following:

            (i)   Accounts (including Health-Care-Insurance Receivables, if
      any);

           (ii)   Chattel Paper;

          (iii)   Instruments (including Promissory Notes);

           (iv)   Documents;

            (v)   General Intangibles (including Payment Intangibles and
      Software);

           (vi)   Letter-of-Credit Rights;

          (vii)   Supporting Obligations;

         (viii)   Deposit Accounts;

           (ix)   Investment Property (including certificated and
      uncertificated Securities, Securities Accounts, Security Entitlements,
      Commodity Accounts, and Commodity Contracts);

            (x)   Inventory;

                                      -2-
<PAGE>
           (xi)   Equipment (including all software, whether or not the same
      constitutes embedded software, used in the operation thereof);

          (xii)   Fixtures;

         (xiii)   All rights to merchandise and other Goods (including rights to
      returned or repossessed Goods and rights of stoppage in transit) which is
      represented by, arises from, or relates to any of the foregoing;

          (xiv)   All personal property and interests in personal property of
      the Company of any kind or description now held by the Lenders or at any
      time hereafter transferred or delivered to, or coming into the possession,
      custody or control of, the Lenders, or any agent or affiliate of the
      Lenders, whether expressly as collateral security or for any other purpose
      (whether for safekeeping, custody, collection or otherwise), and all
      dividends and distributions on or other rights in connection with any such
      property;

           (xv)   All supporting evidence and documents relating to any of the
      above-described property, including, without limitation, computer
      programs, disks, tapes and related electronic data processing media, and
      all rights of the Company to retrieve the same from third parties, written
      applications, credit information, account cards, payment records,
      correspondence, delivery and installation certificates, invoice copies,
      delivery receipts, notes and other evidences of indebtedness, insurance
      certificates and the like, together with all books of account, ledgers and
      cabinets in which the same are reflected or maintained;

          (xvi)   All Accessions and additions to, and substitutions and
      replacements of, any and all of the foregoing; and

         (xvii)   All Proceeds and products of the foregoing, and all
      insurance of the foregoing and proceeds thereof;

all of the foregoing being herein sometimes referred to as the "Collateral". All
terms which are used in this Agreement which are defined in the Uniform
Commercial Code of the State of Illinois as in effect from time to time ("UCC")
shall have the same meanings herein as such terms are defined in the UCC, unless
this Agreement shall otherwise specifically provide. For purposes of this
Agreement, the term "Receivables" means all rights to the payment of a monetary
obligation, whether or not earned by performance, and whether evidenced by an
Account, Chattel Paper, Instrument, General Intangible, or otherwise.

      (b)   This Agreement is made and given to secure, and shall secure, the
payment and performance of (i) any and all indebtedness, obligations and
liabilities of the Company under or in connection with or evidenced by (w) the
Credit Agreement or (x) the Notes of the Company heretofore or hereafter issued
under the Credit Agreement and the obligations of the Company to reimburse the
Agent for the amount of all drawings on all Letters of Credit issued for the
account of the Company pursuant to the Credit Agreement, and all other
obligations of the Company under any and all Applications for such Letters of
Credit or (y) any of the Collateral Documents

                                      -3-
<PAGE>
or (z) agreements with any one or more of the Lenders or their affiliates with
respect to Hedging Liability, in each case whether now existing or hereafter
arising (and whether arising before or after the filing of a petition in
bankruptcy), due or to become due, direct or indirect, absolute or contingent,
and howsoever evidenced, held or acquired and (ii) any and all expenses and
charges, legal or otherwise, suffered or incurred by the Agent and the Lenders
in collecting or enforcing any of such indebtedness, obligations and liabilities
or in realizing on or protecting or preserving any security therefor, including,
without limitation, the lien and security interest granted hereby (all of the
indebtedness, obligations, liabilities, expenses and charges described in
clauses (i) and (ii) above being hereinafter referred to as the "Obligations").

      Section 2.  Terms Defined in Credit Agreement. All capitalized terms used
herein without definition shall have the same meanings herein as such terms have
in the Credit Agreement.

      Section 3.  Covenants, Agreements, Representations and Warranties. The
Company hereby covenants and agrees with, and represents and warrants to, the
Agent and the Lenders that:

            (a)   The Company is a corporation duly organized, validly existing
      and in good standing under the laws of the State of Delaware. The Company
      shall not change its state of organization without the Agent's prior
      written consent. The Company is the sole and lawful owner of the
      Collateral and has full right, power and authority to enter into this
      Agreement and to perform each and all of the matters and things herein
      provided for; and the execution and delivery of this Agreement, and the
      observance and performance of any of the matters and things herein set
      forth, will not contravene or constitute a default under any provision of
      law or any judgment, injunction, order or decree binding upon the Company
      or any provision of the Company's charter, articles of incorporation or
      by-laws or of any covenant, indenture or agreement of or affecting the
      Company or any of its properties, or result in the creation or imposition
      of any lien or encumbrance on any property of the Company. The Company's
      organizational registration number is DE-0938231.

            (b)   The Collateral is and will remain in the Company's possession
      or control at the locations listed under Item 1 on Schedule A attached
      hereto (collectively, the "Permitted Collateral Locations"), except for
      Collateral which in the ordinary course of the Company's business is in
      transit between the Permitted Collateral Locations. If for any reason
      Collateral is at any time kept or located at locations other than the
      Permitted Collateral Locations, the Agent shall nevertheless have and
      retain a security interest therein. The Company owns and will at all times
      own all Permitted Collateral Locations, except to the extent otherwise
      indicated on Schedule A. The Company's chief executive office and
      principal place of business is at, and the Company keeps and shall keep
      all of its books and records relating to Receivables only at, 150 North
      Clinton Street, Chicago, Illinois 60606 and the Company has no other
      executive offices or places of business other than those listed under Item
      2 on Schedule A. The Company will not maintain an executive office or
      place of business at a location other than those specified pursuant to the
      immediately preceding sentence without first providing the Agent 30 days'
      prior

                                      -4-
<PAGE>
      written notice of the Company's intent to do so; provided, however, that
      the Company will at all times maintain its chief executive office in the
      contiguous continental United States of America.

            (c)   The Collateral and every part thereof is and will be free and
      clear of all security interests, liens (including, without limitation,
      mechanics', laborers' and statutory liens), attachments, levies and
      encumbrances of every kind, nature and description and whether voluntary
      or involuntary, except for the security interest of the Agent therein and
      as otherwise permitted by Section 7.11 of the Credit Agreement. The
      Company will warrant and defend the Collateral against any claims and
      demands of all persons or entities at any time claiming the same or any
      interest in the Collateral adverse to the Agent or any Lender.

            (d)   The Company will promptly pay when due all taxes, assessments
      and governmental charges and levies upon or against the Company or the
      Collateral, in each case before the same become delinquent and before
      penalties accrue thereon, unless and to the extent that the same are being
      contested in good faith by appropriate proceedings which prevent
      foreclosure on or other realization upon any Collateral and preclude
      interference with the operation of the Company's business in the ordinary
      course and the Company shall have established adequate reserves therefor.

            (e)   The Company will not waste or destroy the Collateral or any
      part thereof and will not be negligent in the care or use of any
      Collateral. The Company will not use, manufacture, sell or distribute any
      Collateral in violation of any statute, ordinance or other governmental
      requirement. The Company will perform in all material respects its
      obligations under any contract or other agreement constituting part of the
      Collateral, it being understood and agreed that the Agent and the Lenders
      have no responsibility to perform such obligations.

            (f)   Subject to Sections 4(b), 5(a), 6(b) and 6(c) hereof, the
      Company will not, without the Agent's prior written consent, sell, assign,
      mortgage, lease or otherwise dispose of the Collateral or any interest
      therein.

            (g)   The Company will insure the Collateral which is insurable
      against such risks and hazards as other companies similarly situated
      insure against, and including in any event loss or damage by fire, theft,
      burglary, pilferage, loss in transit and such other hazards as the Agent
      may reasonably specify, in amounts and under policies containing loss
      payable clauses to the Agent as its interest may appear (and, if the Agent
      requests, naming the Agent and the Lenders as additional insureds therein)
      by insurers reasonably acceptable to the Agent. All premiums on such
      insurance shall be paid by the Company and the policies of such insurance
      (or certificates therefor) delivered to the Agent. All insurance required
      hereby shall provide that any loss shall be payable notwithstanding any
      act or negligence of the Company, shall provide that no cancellation
      thereof shall be effective until at least thirty (30) days after receipt
      by the Company and the Agent of written notice thereof, and shall be
      satisfactory to the Agent in all other respects. In case of any material
      loss, damage to or destruction of the Collateral or any part thereof, the

                                      -5-
<PAGE>
      Company shall promptly give written notice thereof to the Agent and the
      Lenders generally describing the nature and extent of such damage or
      destruction. In case of any loss, damage to or destruction of the
      Collateral or any part thereof, the Company, whether or not the insurance
      proceeds, if any, received on account of such damage or destruction shall
      be sufficient for that purpose, at the Company's cost and expense, will
      promptly repair or replace the Collateral so lost, damaged or destroyed,
      except to the extent (i) such Collateral, prior to its loss, damage or
      destruction, had become uneconomical, obsolete or worn out or (ii) such
      Collateral is not necessary for or of importance to the proper conduct of
      the Company's business in the ordinary course and such Collateral and all
      other Collateral lost, damaged or destroyed during the immediately
      preceding 12 calendar months had an aggregate fair market value, prior to
      its loss, damage or destruction, of less than $1,000,000. In the event the
      Company shall receive any proceeds of such insurance, the Company will
      immediately pay over such proceeds to the Agent. The Company hereby
      authorizes the Agent, at the Agent's option, to adjust, compromise and
      settle any losses under any insurance afforded at any time after the
      occurrence and during the continuation of any Default or Event of Default,
      and the Company does hereby irrevocably constitute the Agent, its
      officers, agents and attorneys, as the Company's attorneys-in-fact, with
      full power and authority to effect such adjustment, compromise and/or
      settlement and to endorse any drafts drawn by an insurer of the Collateral
      or any part thereof and to do everything necessary to carry out such
      purposes and to receive and receipt for any unearned premiums due under
      policies of such insurance. Unless the Agent elects to adjust, compromise
      or settle losses as aforesaid, any adjustment, compromise and/or
      settlement of any losses under any insurance shall be made by the Company
      subject to final approval of the Agent in the case of losses exceeding
      $1,000,000. Net insurance proceeds received by the Agent under the
      provisions hereof or under any policy or policies of insurance covering
      the Collateral or any part thereof shall be applied to the reduction of
      the Obligations (whether or not then due); provided, however, that the
      Agent agrees to release such insurance proceeds to the Company for
      replacement or restoration of the portion of the Collateral lost, damaged
      or destroyed required by this Agreement to be so replaced or restored if,
      but only if, (i) at the time of release no Default or Event of Default
      exists hereunder, (ii) written application for such release is received
      from the Company within 30 days of receipt of such proceeds and (iii) the
      Agent has received evidence reasonably satisfactory to it that the
      Collateral lost, damaged or destroyed has been or will be replaced or
      restored to its condition immediately prior to the loss, destruction or
      other event giving rise to the payment of such insurance proceeds. All
      insurance proceeds shall be subject to the lien and security interest of
      the Agent hereunder.

            UNLESS THE COMPANY PROVIDES THE AGENT WITH EVIDENCE OF THE INSURANCE
      COVERAGE REQUIRED BY THIS AGREEMENT, THE AGENT MAY PURCHASE INSURANCE AT
      THE COMPANY'S EXPENSE TO PROTECT THE AGENT'S INTERESTS IN THE COLLATERAL.
      THIS INSURANCE MAY, BUT NEED NOT, PROTECT THE COMPANY'S INTERESTS IN THE
      COLLATERAL. THE COVERAGE PURCHASED BY THE AGENT MAY NOT PAY ANY CLAIMS
      THAT THE COMPANY MAKES OR ANY CLAIM THAT IS MADE AGAINST THE COMPANY IN
      CONNECTION WITH THE COLLATERAL. THE COMPANY MAY LATER CANCEL ANY SUCH
      INSURANCE PURCHASED BY THE AGENT, BUT ONLY AFTER

                                      -6-
<PAGE>
      PROVIDING THE AGENT WITH EVIDENCE THAT THE COMPANY HAS OBTAINED INSURANCE
      AS REQUIRED BY THIS AGREEMENT. IF THE AGENT PURCHASES INSURANCE FOR THE
      COLLATERAL, THE COMPANY WILL BE RESPONSIBLE FOR THE COSTS OF THAT
      INSURANCE, INCLUDING INTEREST AND ANY OTHER CHARGES THAT THE AGENT MAY
      IMPOSE IN CONNECTION WITH THE PLACEMENT OF THE INSURANCE, UNTIL THE
      EFFECTIVE DATE OF THE CANCELLATION OR EXPIRATION OF THE INSURANCE. THE
      COSTS OF THE INSURANCE MAY BE ADDED TO THE OBLIGATIONS SECURED HEREBY. THE
      COSTS OF THE INSURANCE MAY BE MORE THAN THE COST OF INSURANCE THE COMPANY
      MAY BE ABLE TO OBTAIN ON ITS OWN.

            (h)   The Company will at all times allow the Agent, any Lender and
      their respective representatives free access to and right of inspection of
      the Collateral, provided that prior to the occurrence of any Default or
      Event of Default hereunder any such access or inspection shall only be
      required during the Company's normal business hours.

            (i)   If any Collateral is in the possession or control of any of
      the Company's agents or processors and the Agent so requests, the Company
      agrees to notify such agents or processors in writing of the Agent's
      security interest therein and instruct them to hold all such Collateral
      for the Agent's account and subject to the Agent's instructions. The
      Company will, upon request of the Agent, authorize and instruct all
      bailees and any other parties, if any, at any time processing, labeling,
      packaging, holding, storing, shipping or transferring all or any part of
      the Collateral to permit the Agent, any Lender and their respective
      representatives to examine and inspect any of the Collateral then in such
      party's possession and to verify from such party's own books and records
      any information concerning the Collateral or any part thereof which the
      Agent, any Lender or their respective representatives may seek to verify.
      As to any premises not owned by the Company wherein any of the Collateral
      is located, if any, the Company shall, unless the Agent requests
      otherwise, cause each party having any right, title or interest in, or
      lien on, any of such premises to enter into an agreement (any such
      agreement to contain a legal description of such premises) whereby such
      party disclaims any right, title and interest in, and lien on, the
      Collateral, allowing the removal of such Collateral by the Agent or by the
      Lenders and otherwise in form and substance acceptable to the Agent;
      provided, however, that no such agreement need be obtained with respect to
      any one location wherein the value of the Collateral as to which such
      agreement has not been obtained aggregates less than $1,000,000 and the
      value of all Collateral as to which such agreements have not been obtained
      aggregates less than $2,000,000.

            (j)   The Company agrees from time to time to deliver to the Agent
      and any Lender such evidence of the existence, identity and location of
      the Collateral and of its availability as collateral security pursuant
      hereto (including, without limitation, schedules describing all
      Receivables created or acquired by the Company, copies of customer
      invoices or the equivalent and original shipping or delivery receipts for
      all merchandise and other goods sold or leased or services rendered,
      together with the Company's warranty of the genuineness thereof, and
      reports stating the book value of Inventory and Equipment by major
      category and location), in each case as the Agent or such Lender may
      reasonably request. The Agent shall have the right to verify all or any
      part of the

                                      -7-
<PAGE>
      Collateral in any manner, and through any medium, which the Agent or the
      Lenders consider appropriate, and the Company agrees to furnish all
      assistance and information, and perform any acts, which the Agent may
      reasonably require in connection therewith. The Company will promptly
      notify the Agent and each Lender of any Collateral which the Company has
      determined to have been rendered obsolete stating the prior book value of
      such Collateral, its type and location.

            (k)   The Company will comply in all material respects with the
      terms and conditions of any and all leases, easements, right-of-way
      agreements and other agreements binding upon the Company or affecting the
      Collateral, in each case which cover the premises wherein the Collateral
      is located, and any orders, ordinances, laws or statutes of any city,
      state or other governmental entity, department or agency having
      jurisdiction with respect to such premises or the conduct of business
      thereon.

            (l)   The Company has not invoiced Receivables or otherwise
      transacted business, and does not invoice Receivables or otherwise
      transact business, under any trade names other than the Company's name set
      forth in the introductory paragraph of this Agreement. The Company will
      not change its name or transact business under any other trade name, in
      each case without first giving the Agent 30 days' prior written notice of
      its intent to do so.

            (m)   The Company agrees to execute and deliver to the Agent such
      further agreements and assignments or other instruments and documents and
      to do all such other things as the Agent may reasonably deem necessary or
      appropriate to assure the Agent its security interest hereunder, including
      (i) such financing statement or statements or amendments thereof or
      supplements thereto or other instruments and documents as the Agent may
      from time to time reasonably require in order to comply with the Uniform
      Commercial Code as enacted in the State of Illinois and any successor
      statute(s) thereto (the "Code") and (ii) such control agreements with
      respect to all Deposit Accounts, Securities Accounts, Letter-of-Credit
      Rights, and electronic Chattel Paper, and to use commercially reasonable
      efforts to cause the relevant depository institutions, financial
      intermediaries, and letter of credit issuers to execute and deliver such
      control agreements, as the Lenders may from time to time require. The
      Company hereby agrees that a carbon, photographic or other reproduction of
      this Agreement or any such financing statement is sufficient for filing as
      a financing statement by the Agent without notice thereof to the Company
      wherever the Agent in its sole discretion desires to file the same. The
      Company hereby authorizes the Lenders to file any and all financing
      statements covering the Collateral or any part thereof as the Lenders may
      require, including financing statements describing the Collateral as "all
      assets" or "all personal property" or words of like meaning. The Lenders
      may order lien searches from time to time against the Company and the
      Collateral, and the Company shall promptly reimburse the Lenders for all
      reasonable costs and expenses incurred in connection with such lien
      searches. In the event for any reason the law of any jurisdiction other
      than Illinois becomes or is applicable to the Collateral or any part
      thereof, or to any of the Obligations, the Company agrees to execute and
      deliver all such instruments and documents and to do all such other things
      as the Agent in its sole discretion deems necessary or appropriate to
      preserve, protect and

                                      -8-
<PAGE>
      enforce the security interest of the Agent under the law of such other
      jurisdiction. The Company agrees to mark its books and records to reflect
      the security interest of the Agent in the Collateral.

            (n)   On failure of the Company to perform any of the covenants and
      agreements herein contained, the Agent may at its option perform the same
      and in so doing may expend such sums as the Agent may reasonably deem
      advisable in the performance thereof, including, without limitation, the
      payment of any insurance premiums, the payment of any taxes, liens and
      encumbrances, expenditures made in defending against any adverse claims,
      and all other expenditures which the Agent may be compelled to make by
      operation of law or which the Agent may make by agreement or otherwise for
      the protection of the security hereof. All such sums and amounts so
      expended shall be repayable by the Company immediately without notice or
      demand, shall constitute additional Obligations secured hereunder and
      shall bear interest from the date said amounts are expended at the rate
      per annum (computed on the basis of a 360-day year for the actual number
      of days elapsed) determined by adding 2% to the Domestic Rate as from time
      to time in effect with any change in such rate per annum as so determined
      by reason of a change in such Domestic Rate to be effective on the date of
      such change in said Domestic Rate (such rate per annum as so determined
      being hereinafter referred to as the "Default Rate"). No such performance
      of any covenant or agreement by the Agent on behalf of the Company, and no
      such advancement or expenditure therefor, shall relieve the Company of any
      default under the terms of this Agreement or in any way obligate the Agent
      or any Lender to take any further or future action with respect thereto.
      The Agent in making any payment hereby authorized may do so according to
      any bill, statement or estimate procured from the appropriate public
      office or holder of the claim to be discharged without inquiry into the
      accuracy of such bill, statement or estimate or into the validity of any
      tax assessment, sale, forfeiture, tax lien or title or claim. The Agent in
      performing any act hereunder shall be the sole judge of whether the
      Company is required to perform the same under the terms of this Agreement.
      The Agent is hereby authorized to charge any depository or other account
      of the Company maintained with the Agent for the amount of such sums and
      amounts so expended.

      Section 4.  Special Provisions Re: Receivables.

      (a)   As of the time any Receivable becomes subject to the security
interest provided for hereby and at all times thereafter, the Company shall be
deemed to have warranted as to each and all of such Receivables that all
warranties of the Company set forth in this Agreement are true and correct with
respect to each such Receivable; that each Receivable and all papers and
documents relating thereto are genuine and in all respects what they purport to
be; that each Receivable is valid and subsisting and, if such Receivable is an
Account, arises out of a bona fide sale of goods sold and delivered by the
Company to, or in the process of being delivered to, or out of and for services
theretofore actually rendered by the Company to, the account debtor named
therein; that no such Receivable is evidenced by any Instrument or Chattel Paper
unless such instrument or chattel paper has theretofore been endorsed by the
Company and delivered to the Agent (except to the extent the Agent specifically
requests the Company not to do so with

                                      -9-
<PAGE>
respect to any such Instrument or Chattel Paper); that no surety bond was
required or given in connection with such Receivable or the contracts or
purchase orders out of which the same arose; and that if said Receivable is
scheduled, listed or referred to on any certificate evidencing the Borrowing
Base or is otherwise a Receivable which the Company wants the Lenders to
consider as an Eligible Account, that said Receivable qualifies as an Eligible
Account. Without limiting the foregoing, if any Receivable which the Company
desires to qualify as an Eligible Account arises out of a contract with the
United States of America or any of its departments, agencies or
instrumentalities, the Company agrees to notify the Agent and execute whatever
instruments and documents are required by the Agent in order that such
Receivable shall be assigned to the Agent and that proper notice of such
assignment shall be given under the federal Assignment of Claims Act (or any
successor statute).

            (b)   Unless and until an Event of Default hereunder occurs, any
merchandise or other goods which are returned by a customer or account debtor or
otherwise recovered may be resold by the Company in the ordinary course of its
business as presently conducted in accordance with Section 6(b) hereof; upon the
occurrence and during the continuation of any Event of Default hereunder, such
merchandise and other goods shall be set aside at the request of the Agent and
held by the Company as trustee for the Agent and the Lenders and shall remain
part of the Collateral. Unless and until an Event of Default hereunder occurs,
the Company may settle and adjust disputes and claims with its customers and
account debtors, handle returns and recoveries and grant discounts, credits and
allowances in the ordinary course of its business as presently conducted for
amounts and on terms which the Company in good faith considers advisable. Upon
the occurrence and during the continuation of any Event of Default hereunder,
unless the Agent requests otherwise, the Company shall notify the Agent promptly
of all returns and recoveries and, on the Agent's request, deliver any such
merchandise or other goods to the Agent. Upon the occurrence and during the
continuation of any Event of Default hereunder, unless the Agent requests
otherwise, the Company shall also notify the Agent promptly of all disputes and
claims and settle or adjust them at no expense to the Agent or the Lenders
hereunder, but no discount, credit or allowance other than on normal trade terms
in the ordinary course of business as presently conducted shall be granted to
any customer or account debtor and no returns of merchandise or other goods
shall be accepted by the Company without the Agent's consent. The Agent may, at
all times upon the occurrence and during the continuation of any Event of
Default hereunder, settle or adjust disputes and claims directly with customers
or account debtors for amounts and upon terms which the Agent considers
advisable.

            (c)   Unless delivered to the Lenders or its Agent, all tangible
Chattel Paper and Instruments shall contain a legend acceptable to the Lenders
indicating that such Chattel Paper or Instrument is subject to the security
interest of the Lenders contemplated by this Agreement

      Section 5.  Collection of Receivables.

      (a)   Except as otherwise provided in this Agreement, the Company shall
make collection of all Receivables and may use the same to carry on its business
in accordance with sound business practice and otherwise subject to the terms
hereof.

                                      -10-
<PAGE>
      (b)   Whether or not any Default or Event of Default has occurred
hereunder and whether or not the Agent has exercised any or all of its rights
under other provisions of this Section 5, in the event the Agent requests the
Company to do so:

            (i)   all Instruments and Chattel Paper at any time constituting
      part of the Receivables (including any postdated checks) shall, upon
      receipt by the Company, be immediately endorsed to and deposited with
      Agent; and/or

           (ii)   the Company shall instruct all customers and account debtors
      to remit all payments in respect of Receivables to a lockbox or lockboxes
      under the sole custody and control of Agent and which are maintained at
      post offices selected by the Agent.

      (c)   Upon the occurrence and during the continuation of any Default or
Event of Default hereunder, whether or not the Agent has exercised any or all of
its rights under other provisions of this Section 5, the Agent or its designee
may notify the Company's customers and account debtors at any time that
Receivables have been assigned to the Agent or of the Agent's security interest
therein, and either in its own name, or the Company's name, or both, demand,
collect (including, without limitation, through a lockbox analogous to that
described in Section 5(b)(ii) hereof), receive, receipt for, sue for, compound
and give acquittance for any or all amounts due or to become due on Receivables,
and in the Agent's discretion file any claim or take any other action or
proceeding which the Agent may deem reasonably necessary or appropriate to
protect and realize upon the security interest of the Agent in the Receivables.

      (d)   Any proceeds of Receivables or other Collateral transmitted to or
otherwise received by the Agent pursuant to any of the provisions of Sections
5(b) or 5(c) hereof may be handled and administered by the Agent in and through
a remittance account or accounts maintained at the Agent or by the Agent at a
commercial bank or banks selected by the Agent (each a "Depositary Bank"), and
the Company acknowledges that the maintenance of such remittance accounts by the
Agent is solely for the Agent's convenience and that the Company does not have
any right, title or interest in such remittance accounts or any amounts at any
time standing to the credit thereof. The Agent may apply all or any part of any
proceeds of Receivables or other Collateral received by it from any source to
the payment of the Obligations (whether or not then due and payable), such
applications to be made in such amounts, in such manner and order and at such
intervals as the Agent may from time to time in its discretion determine, but
not less often than once each week. The Agent need not apply or give credit for
any item included in proceeds of Receivables or other Collateral until the
relevant Depositary Bank has received final payment therefor at its office in
cash or final solvent credits current at the site of deposit acceptable to the
Agent and the relevant Depositary Bank as such. However, if the Agent does
permit credit to be given for any item prior to a Depositary Bank receiving
final payment therefor and such Depositary Bank fails to receive such final
payment or an item is charged back to the Agent or any Depositary Bank for any
reason, the Agent may at its election in either instance charge the amount of
such item back against any such remittance accounts or any depository account of
the Company maintained with the Agent, together with interest thereon at the
Default Rate. Concurrently with each transmission of any proceeds of Receivables
or other Collateral to any remittance account, the Company shall furnish the
Agent with a report in such form as Agent shall reasonably require identifying
the particular Receivable or such other Collateral from which the same arises or

                                      -11-
<PAGE>
relates. Unless and until a Default or an Event of Default shall have occurred
and be continuing hereunder, the Agent will cause proceeds of Collateral which
the Agent has not applied to the Obligations as provided above to be released
from the remittance accounts from time to time or otherwise make such proceeds
available to the Company at its request, but not less often than once per week.
The Company hereby indemnifies the Agent and the Lenders from and against all
liabilities, damages, losses, actions, claims, judgments, costs, expenses,
charges and attorneys' fees suffered or incurred by the Agent or any Lender
because of the maintenance of the foregoing arrangements; provided, however,
that the Company shall not be required to indemnify the Agent or any Lender for
any of the foregoing to the extent they arise solely from the gross negligence
or willful misconduct of the person seeking to be indemnified. The Agent and the
Lenders shall have no liability or responsibility to the Company for the Agent
or any other Depositary Bank accepting any check, draft or other order for
payment of money bearing the legend "payment in full" or words of similar import
or any other restrictive legend or endorsement whatsoever or be responsible for
determining the correctness of any remittance.

      Section 6.  Special Provisions Re: Inventory and Equipment.

      (a)   The Company will at its own cost and expense maintain, keep and
preserve the Inventory in good and merchantable condition and keep and preserve
the Equipment in good repair, working order and condition, ordinary wear and
tear excepted, and, without limiting the foregoing, make all necessary and
proper repairs, replacements and additions to the Equipment so that the
efficiency thereof shall be fully preserved and maintained.

      (b)   The Company may, until an Event of Default has occurred and is
continuing and thereafter until otherwise notified by the Agent, use, consume
and sell the Inventory in the ordinary course of its business, but a sale in the
ordinary course of business shall not under any circumstance include any
transfer or sale in satisfaction, partial or complete, of a debt owing by the
Company.

      (c)   The Company may, until an Event of Default has occurred and is
continuing and thereafter until otherwise notified by the Agent, sell (i)
obsolete, worn out or unusable Equipment which is concurrently replaced with
similar Equipment at least equal in quality and condition to that sold and owned
by the Company free of any lien, charge or encumbrance other than the security
interest granted hereby and (ii) Equipment which this Agreement would not
require the Company to repair or replace if the same were lost, damaged or
destroyed pursuant to Section 3(g) hereof.

      (d)   As of the time any Inventory or Equipment becomes subject to the
security interest provided for hereby and at all times thereafter, the Company
shall be deemed to have warranted as to any and all of such Inventory and
Equipment that all warranties of the Company set forth in this Agreement are
true and correct with respect to such Inventory and Equipment; that all of such
Inventory and Equipment is located at a location set forth pursuant to Section
3(b) hereof. The Company warrants and agrees that no Inventory is or will be
consigned to any other person or entity without the Agent's prior written
consent.

                                      -12-
<PAGE>
      (e)   Upon the Agent's request, the Company shall at its own cost and
expense cause the lien of the Agent in and to any portion of the Collateral
subject to a certificate of title law to be duly noted on such certificate of
title or to be otherwise filed in such manner as is prescribed by law in order
to perfect such lien and will cause all such certificates of title and evidences
of lien to be deposited with the Agent.

      (f)   Except for Equipment from time to time located on the real estate
described on Schedule B attached hereto and as otherwise disclosed to the
Lenders in writing, none of the Equipment is or will be attached to real estate
in such a manner that the same may become a fixture.

      (g)   If any of the Inventory is at any time evidenced by a document of
title, such document shall be promptly delivered by the Company to the Agent.

      Section 7.  Special Provisions Re: Investment Property and Deposits.

      (a)   Unless and until an Event of Default has occurred and is continuing
and thereafter until notified to the contrary by the Agent pursuant to Section
9(d) hereof:

            (i)   The Company shall be entitled to exercise all voting and/or
      consensual powers pertaining to the Investment Property or any part
      thereof, for all purposes not inconsistent with the terms of this
      Agreement or any other document evidencing or otherwise relating to any
      Obligations; and

           (ii)   The Company shall be entitled to receive and retain all cash
      dividends paid upon or in respect of the Investment Property.

      (b)   All Investment Property of the Company (including all securities,
certificated or uncertificated, securities accounts, and commodity accounts)
maintained by the Company on the date hereof is listed and identified on
Schedule C attached hereto and made a part hereof. The Company shall promptly
notify the Agent of any other Investment Property acquired or maintained by the
Company after the date hereof, and shall submit to the Agent a supplement to
Schedule C to reflect such additional rights (provided the Company's failure to
do so shall not impair the Agent's security interest therein). Certificates for
all certificated securities now or at any time constituting Investment Property
shall, at the Agent's request, be promptly delivered by the Company to the Agent
duly endorsed in blank for transfer or accompanied by an appropriate assignment
or assignments or an appropriate undated stock power or powers, in every case
sufficient to transfer title thereto, including, without limitation, all stock
received in respect of a stock dividend or resulting from a split-up, revision,
or reclassification of the Investment Property or any part thereof or received
in addition to, in substitution of, or in exchange for the Investment Property
or any part thereof as a result of a merger, consolidation, or otherwise. With
respect to any uncertificated securities or any Investment Property held by a
securities intermediary, commodity intermediary, or other financial intermediary
of any kind, at the Agent's request, the Company shall execute and deliver, and
shall cause any such issuer or intermediary to execute and deliver, an agreement
among the Company, the Agent, and such issuer or intermediary in form and
substance reasonably satisfactory to the Agent which

                                      -13-
<PAGE>
provides, among other things, for the intermediary's agreement that it shall
comply with entitlement orders, and apply any value distributed on account of
any Investment Property maintained in an account with such intermediary, as
directed by the Agent without further consent by the Company. The Agent may at
any time, after the occurrence of an Event of Default or an event or condition
which with the lapse of time or the giving of notice, or both, would constitute
an Event of Default, cause to be transferred into its name or the name of its
nominee or nominees all or any part of the Investment Property hereunder.

      (c)   Unless and until an Event of Default, or an event or condition which
with the lapse of time or the giving of notice, or both, would constitute an
Event of Default, has occurred and is continuing, the Company may sell or
otherwise dispose of any Investment Property, provided that sales or other
dispositions of capital stock or other equity interests of any direct or
indirect Subsidiary shall be in accordance with the terms of the Credit
Agreement. After the occurrence and during the continuation of any Event of
Default or of any event or condition which with the lapse of time or the giving
of notice, or both, would constitute an Event of Default, the Company shall not
sell all or any part of the Investment Property without the prior written
consent of the Agent.

      (d)   The Company represents that on the date of this Agreement, none of
the Investment Property consists of margin stock (as such term is defined in
Regulation U of the Board of Governors of the Federal Reserve System) except to
the extent the Company has delivered to the Agent a duly executed and completed
Form U-1 with respect to such stock. If at any time the Investment Property or
any part thereof consists of margin stock, the Company shall promptly so notify
the Agent and deliver to the Agent a duly executed and completed Form U-1 and
such other instruments and documents reasonably requested by the Agent in form
and substance reasonably satisfactory to the Agent.

      (e)   Notwithstanding anything to the contrary contained herein, in the
event any Investment Property is subject to the terms of a separate security
agreement in favor of the Agent, the terms of such separate security agreement
shall govern and control unless otherwise agreed to in writing by the Agent.

      (f)   All Deposit Accounts maintained by the Company on the date hereof
are listed and identified (by account number and depository institution) on
Schedule C attached hereto and made a part hereof. The Company shall promptly
notify the Agent of any other Deposit Account opened or maintained by the
Company after the date hereof, and shall submit to the Agent a supplement to
Schedule C to reflect such additional accounts (provided the Company's failure
to do so shall not impair the Agent's security interest therein). With respect
to any Deposit Account maintained by a depository institution other than the
Agent, and as a condition to the establishment and maintenance of any such
Deposit Account the Company, the depository institution, and the Lender shall
execute and deliver an account control agreement in form and substance
satisfactory to the Lender which provides, among other things, for the
depository institution's agreement that it will comply with instructions
originated by the Agent directing the disposition of the funds in the Deposit
Account without further consent by such Company.

                                      -14-
<PAGE>
      Section 8.  Power of Attorney. In addition to any other powers of attorney
contained herein, the Company hereby appoints the Agent, its nominee, or any
other person whom the Agent may designate as the Company's attorney-in-fact,
with full power upon the occurrence and during the continuation of an Event of
Default hereunder to sign the Company's name on verifications of accounts, to
send requests for verification of Receivables to the Company's customers and
account debtors, to endorse the Company's name on any checks, notes,
acceptances, money orders, drafts and any other forms of payment or security
that may come into the Agent's possession, to sign the Company's name on any
invoice or bill of lading relating to any Receivables, on claims to enforce
collection of any Receivable, on notices to and drafts against customers and
account debtors, on schedules and assignments of Receivables, on notices of
assignment and on public records, to notify the post office authorities to
change the address for delivery of the Company's mail to an address designated
by the Agent, to receive, open and dispose of all mail addressed to the Company
and to do all things necessary to carry out this Agreement. The Company hereby
ratifies and approves all acts of any such attorney and agrees that neither the
Agent nor any such attorney will be liable for any acts or omissions nor for any
error of judgment or mistake of fact or law other than their gross negligence or
willful misconduct. The foregoing power of attorney, being coupled with an
interest, is irrevocable until the Obligations have been fully paid and
satisfied and the commitments of the Lenders to extend credit to or for the
account of the Company under the Credit Agreement have terminated. The Agent may
file one or more financing statements disclosing its security interest in any or
all of the Collateral without the Company's signature appearing thereon. The
Company also hereby grants the Agent a power of attorney to execute any such
financing statements, or amendments and supplements to financing statements, on
behalf of the Company without notice thereof to the Company, which power of
attorney is coupled with an interest and is irrevocable until the Obligations
have been fully paid and satisfied and the commitments of the Lenders to extend
credit to or for the account of the Company under the Credit Agreement have
terminated.

      Section 9.  Defaults and Remedies.

      (a)   The occurrence of any event or the existence of any condition which
is specified as an "Event of Default" under the Credit Agreement shall
constitute an "Event of Default" hereunder.

      (b)   Upon the occurrence and during the continuation of any Event of
Default hereunder, the Agent shall have, in addition to all other rights
provided herein or by law, the rights and remedies of a secured party under the
Code (regardless of whether the Code is the law of the jurisdiction where the
rights or remedies are asserted and regardless of whether the Code applies to
the affected Collateral), and further the Agent may, without demand and without
advertisement, notice, hearing or process of law, all of which the Company
hereby waives, at any time or times, sell and deliver any or all Collateral held
by or for it at public or private sale, for cash, upon credit or otherwise, at
such prices and upon such terms as the Agent deems advisable, in its sole
discretion. In addition to all other sums due the Agent or any Lender hereunder,
the Company shall pay the Agent and any Lender all costs and expenses incurred
by the Agent or such Lender, including attorneys' fees and court costs, in
obtaining, liquidating or enforcing payment of Collateral or the Obligations or
in the prosecution or defense of any action or proceeding by or against the
Agent, such Lender or the Company concerning any matter arising

                                      -15-
<PAGE>
out of or connected with this Agreement or the Collateral or the Obligations,
including, without limitation, any of the foregoing arising in, arising under or
related to a case under the United States Bankruptcy Code (or any successor
statute). Any requirement of reasonable notice shall be met if such notice is
personally served on or mailed, postage prepaid, to the Company in accordance
with Section 13(b) hereof at least ten days before the time of sale or other
event giving rise to the requirement of such notice; provided however, no
notification need be given to the Company if the Company has signed, after an
Event of Default hereunder has occurred, a statement renouncing any right to
notification of sale or other intended disposition. The Agent shall not be
obligated to make any sale or other disposition of the Collateral regardless of
notice having been given. The Agent or any Lender may be the purchaser at any
such sale. The Company hereby waives all of its rights of redemption from any
such sale. Subject to the provisions of applicable law, the Agent may postpone
or cause the postponement of the sale of all or any portion of the Collateral by
announcement at the time and place of such sale, and such sale may, without
further notice, be made at the time and place to which the sale was postponed or
the Agent may further postpone such sale by announcement made at such time and
place. The Agent and the Lenders have no obligation to prepare the Collateral
for sale. The Agent and the Lenders may sell or otherwise dispose of the
Collateral without giving any warranties as to the Collateral or any part
thereof, including disclaimers of any warranties of title or the like, and the
Company acknowledges and agrees that the absence of such warranties shall not
render the disposition commercially unreasonable.

      (c)   Without in any way limiting the foregoing, upon the occurrence and
during the continuation of any Event of Default hereunder, the Agent shall have
the right, in addition to all other rights provided herein or by law, to take
physical possession of any and all of the Collateral and anything found therein,
the right for that purpose to enter without legal process any premises where the
Collateral may be found (provided such entry be done lawfully), and the right to
maintain such possession on the Company's premises (the Company hereby agreeing
to lease such premises without cost or expense to the Agent or its designee if
the Agent so requests) or to remove the Collateral or any part thereof to such
other places as the Agent may desire. Upon the occurrence and during the
continuation of any Event of Default hereunder, the Agent shall have the right
to exercise any and all rights with respect to all Deposit Accounts of the
Company, including, without limitation, the right to direct the disposition of
the funds in each Deposit Account and to collect, withdraw and receive all
amounts due or to become due or payable under each such Deposit Account. Upon
the occurrence and during the continuation of any Event of Default hereunder,
the Company shall, upon the Agent's demand, promptly assemble the Collateral and
make it available to the Agent at a place designated by the Agent. If the Agent
exercises its right to take possession of the Collateral, the Company shall also
at its expense perform any and all other steps requested by the Agent to
preserve and protect the security interest hereby granted in the Collateral,
such as placing and maintaining signs indicating the security interest of the
Agent, appointing overseers for the Collateral and maintaining Collateral
records.

      (d)   Without in any way limiting the foregoing, upon the occurrence and
during the continuation of any Event of Default, all rights of the Company to
exercise the voting and/or consensual powers which it is entitled to exercise
pursuant to Section 7(a)(i) hereof and/or to receive and retain the
distributions which it is entitled to receive and retain pursuant to

                                      -16-
<PAGE>
Section 7(a)(ii) hereof, shall, at the option of the Agent, cease and thereupon
become vested in the Agent, which, in addition to all other rights provided
herein or by law, shall then be entitled solely and exclusively to exercise all
voting and other consensual powers pertaining to the Investment Property
(including, without limitation, the right to deliver notice of control with
respect to any Investment Property held in a securities account or commodity
account and deliver all entitlement orders with respect thereto) and/or to
receive and retain the distributions which the Company would otherwise have been
authorized to retain pursuant to Section 7(a)(ii) hereof and shall then be
entitled solely and exclusively to exercise any and all rights of conversion,
exchange, or subscription or any other rights, privileges, or options pertaining
to any Investment Property as if the Agent were the absolute owner thereof.
Without limiting the foregoing, the Agent shall have the right to exchange, at
its discretion, any and all of the Investment Property upon the merger,
consolidation, reorganization, recapitalization, or other readjustment of the
respective issuer thereof or upon the exercise by or on behalf of any such
issuer or the Agent of any right, privilege, or option pertaining to any
Investment Property and, in connection therewith, to deposit and deliver any and
all of the Investment Property with any committee, depositary, transfer agent,
registrar, or other designated agency upon such terms and conditions as the
Agent may determine. In the event the Agent in good faith believes any of the
Collateral constitutes restricted securities within the meaning of any
applicable securities laws, any disposition thereof in compliance with such laws
shall not render the disposition commercially unreasonable.

      (e)   Without in any way limiting the foregoing, the Company hereby grants
to the Agent and the Lenders a royalty-free irrevocable license and right to use
all of the Company's patents, patent applications, patent licenses, trademarks,
trademark registrations, trademark licenses, trade names, trade styles, and
similar intangibles in connection with any foreclosure or other realization by
the Agent or the Lenders on all or any part of the Collateral. The license and
right granted the Agent and the Lenders hereby shall be without any royalty or
fee or charge whatsoever.

      (f)   The powers conferred upon the Agent hereunder are solely to protect
its interest in the Collateral and shall not impose on it any duty to exercise
such powers. The Agent shall be deemed to have exercised reasonable care in the
custody and preservation of the Collateral its possession or control if such
Collateral is accorded treatment substantially equivalent to that which the
Agent accords its own property, consisting of similar type assets, it being
understood, however, that the Agent shall have no responsibility for
ascertaining or taking any action with respect to calls, conversions, exchanges,
maturities, tenders, or other matters relating to any such Collateral, whether
or not the Agent has or is deemed to have knowledge of such matters. This
Agreement constitutes an assignment of rights only and not an assignment of any
duties or obligations of the Company in any way related to the Collateral, and
the Agent shall have no duty or obligation to discharge any such duty or
obligation. The Agent shall have no responsibility for taking any necessary
steps to preserve rights against any parties with respect to any Collateral or
initiating any action to protect the Collateral against the possibility of a
decline in market value. Neither the Agent nor any party acting as attorney for
the Agent shall be liable for any acts or omissions or for any error of judgment
or mistake of fact or law other than their gross negligence or willful
misconduct.

                                      -17-
<PAGE>
      (g)   Failure by the Agent to exercise any right, remedy or option under
this Agreement or any other agreement between the Company and the Agent or
provided by law, or delay by the Agent in exercising the same, shall not operate
as a waiver; and no waiver shall be effective unless it is in writing, signed by
the party against whom such waiver is sought to be enforced and then only to the
extent specifically stated. Neither the Agent or any Lender, nor any party
acting as attorney for the Agent or any Lender, shall be liable hereunder for
any acts or omissions or for any error of judgment or mistake of fact or law
other than their gross negligence or willful misconduct. The rights and remedies
of the Agent and the Lenders under this Agreement shall be cumulative and not
exclusive of any other right or remedy which the Agent or the Lenders may have.
For purposes of this Agreement, a Default or Event of Default shall be construed
as continuing after its occurrence until the same is waived in writing by the
Lenders or the Required Lenders, as the case may be, in accordance with the
Credit Agreement or, in the case of a Default, the same is cured by the Company
within any applicable cure period.

      Section 10.  Application of Proceeds. The proceeds and avails of the
Collateral at any time received by the Agent upon the occurrence and during the
continuation of any Event of Default hereunder shall, when received by the Agent
in cash or its equivalent, be applied by the Agent as follows:

            (a)   first, to the payment of any outstanding costs and expenses
      incurred by the Agent in monitoring, verifying, protecting, preserving or
      enforcing the Liens on the Collateral, and in protecting, preserving or
      enforcing rights under this Agreement or any of the other Loan Documents,
      and in any event including all costs and expenses of a character which the
      Company has agreed to pay under Section 11.15 of the Credit Agreement
      (such funds to be retained by the Agent for its own account unless it has
      previously been reimbursed for such costs and expenses by the Lenders, in
      which event such amounts shall be remitted to the Lenders to reimburse
      them for payments theretofore made to the Agent);

            (b)   second, to the payment of any outstanding interest or other
      fees or amounts due under this Agreement or any of the other Loan
      Documents other than for principal, pro rata as among the Agent and the
      Lenders in accord with the amount of such interest and other fees or
      amounts owing each;

            (c)   third, to the payment of the principal of the Notes and any
      liabilities in respect of unpaid drawings under the Letters of Credit, pro
      rata as among the Lenders in accord with the then respective unpaid
      principal balances of the Notes and the then unpaid liabilities in respect
      of unpaid drawings under the Letters of Credit;

            (d)   fourth, to the Agent, to be held as collateral security for
      any undrawn Letters of Credit, until the Agent is holding an amount of
      cash equal to the then outstanding amount of all Letters of Credit; and

            (e)   fifth, to the Agent and the Lenders pro rata in accord with
      the amounts of any other Obligations (including, without limitation,
      Hedging Liability) owing to them

                                      -18-
<PAGE>
      and secured hereby unless and until all such Obligations have been fully
      paid and satisfied.

The Company shall remain liable to the Agent and the Lenders for any deficiency.
Any surplus remaining after the full payment and satisfaction of the Obligations
shall be returned to the Company or to whomsoever the Agent reasonably
determines is lawfully entitled thereto.

      Section 11.  Continuing Agreement. This Agreement shall be a continuing
agreement in every respect and shall remain in full force and effect until all
of the Obligations, both for principal and interest, have been fully paid and
satisfied and the commitments of the Lenders to extend credit to or for the
account of the Company under the Credit Agreement have terminated. Upon such
termination of this Agreement, the Agent shall, upon the request and at the
expense of the Company, forthwith release its security interest hereunder.

      Section 12.  The Agent. In acting under or by virtue of this Agreement,
the Agent shall be entitled to all the rights, authority, privileges and
immunities provided in Section 10 of the Credit Agreement, all of which
provisions of said Section 10 are incorporated by reference herein with the same
force and effect as if set forth herein in their entirety. The Agent hereby
disclaims any representation or warranty to the Lenders concerning the
perfection of the security interest granted hereunder or in the value of any of
the Collateral.

      Section 13.  Miscellaneous.

      (a)   This Agreement cannot be changed or terminated orally. This
Agreement shall create a continuing security interest in the Collateral and
shall be binding upon the Company, its successors and assigns and shall inure,
together with the rights and remedies of the Agent and the Lenders hereunder, to
the benefit of the Agent, the Lenders, and their successors and assigns;
provided, however, that the Company may not assign its rights or delegate its
duties hereunder without the Agent's prior written consent. Without limiting the
generality of the foregoing, and subject to the provisions of Section 11.12 of
the Credit Agreement, any Lender may assign or otherwise transfer any
indebtedness held by it secured by this Agreement to any other person or entity,
and such other person or entity shall thereupon become vested with all the
benefits in respect thereof granted to such Lender herein or otherwise, subject,
however, to the provisions of the Credit Agreement. The Company hereby releases
the Agent and each Lender from any liability for any act or omission relating to
the Collateral or this Agreement, except for the Agent's or such Lender's gross
negligence or willful misconduct.

      (b)   Except as otherwise specified herein, all notices hereunder shall be
in writing (including, without limitation, notice by telecopy) and shall be
given to the relevant party, and shall be deemed to have been made when given to
the relevant party, in accordance with Section 11.8 of the Credit Agreement.

      (c)   No Lender shall have the right to institute any suit, action or
proceeding in equity or at law for the foreclosure or other realization upon any
Collateral subject to this Agreement or for the execution of any trust or power
hereof or for the appointment of a receiver, or for the enforcement of any other
remedy under or upon this Agreement; it being understood and

                                      -19-
<PAGE>
intended that no one or more of the Lenders shall have any right in any manner
whatsoever to affect, disturb or prejudice the lien and security interest of
this Agreement by its or their action or to enforce any right hereunder, and
that all proceedings at law or in equity shall be instituted, had and maintained
by the Agent in the manner herein provided for the benefit of the Lenders.

      (d)   In the event that any provision hereof shall be deemed to be invalid
or unenforceable by reason of the operation of any law or by reason of the
interpretation placed thereon by any court, this Agreement shall be construed as
not containing such provision, but only as to such jurisdictions where such law
or interpretation is operative, and the invalidity or unenforceability of such
provision shall not affect the validity of any remaining provisions hereof, and
any and all other provisions hereof which are otherwise lawful and valid shall
remain in full force and effect.

      (e)   This Agreement shall be deemed to have been made in the State of
Illinois and shall be governed by, and construed in accordance with, the laws of
the State of Illinois. All terms which are used in this Agreement which are
defined in the Code shall have the same meanings herein as said terms do in the
Code unless this Agreement shall otherwise specifically provide. The headings in
this Agreement are for convenience of reference only and shall not limit or
otherwise affect the meaning of any provision hereof.

      (f)   This Agreement may be executed in any number of counterparts and by
different parties hereto on separate counterpart signature pages, each
constituting an original, but all together one and the same agreement.

      (g)   Upon the execution and delivery of this Agreement by the Company and
the Agent, on behalf of the Lenders, this Agreement shall supersede all
provisions of the Prior Security Agreement as of such date. The Company hereby
agrees that, notwithstanding the execution and delivery of this Agreement, the
liens and security interests created and provided for under the Prior Security
Agreement continue in effect under and pursuant to the terms of this Agreement
for the benefit of all of the Obligations secured hereby. Nothing herein
contained shall in any manner affect or impair the priority of the liens and
security interests created and provided for by the Prior Security Agreement as
to the indebtedness and obligations which would otherwise be secured thereby
prior to giving effect to this Agreement.

                                      -20-
<PAGE>
      IN WITNESS WHEREOF, the Company has caused this Agreement to be duly
executed and delivered as of the date first above written.

                                       INFORMATION RESOURCES, INC.

                                       By
                                          Name________________________________
                                          Title_______________________________

      Accepted and agreed to as of the date first above written.

                                       HARRIS TRUST AND SAVINGS BANK, as
                                          Agent as aforesaid for the Lenders

                                       By
                                          Name________________________________
                                          Title_______________________________

                                      -21-
<PAGE>
                                   SCHEDULE A

                                    LOCATIONS

Item 1. Debtor's chief financial office and principal place of business:

          150 North Clinton Street
          Chicago, Illinois  60606

Item 2. Additional Places of Business and/or Permitted Collateral Locations:

        IRI CORPORATE AND BRANCH OFFICES

<TABLE>
<CAPTION>
        OFFICE LOCATION        STREET ADDRESS                         CITY             STATE     ZIP
<S>                            <C>                                    <C>              <C>       <C>
        Chicago                150 N. Clinton                         Chicago          IL        60661
        Chicago (12/1/2000)    550 W. Washington                      Chicago          IL        60661
        Chicago                564 W. Randolph                        Chicago          IL        60661
        Chicago                5515 N. Cumberland                     Chicago          IL        60656
        Wood Dale              341-361 Haynes Drive                   Wood Dale        IL        60191
        Atlanta                7840 Rosewell Road, Building #100,     Atlanta          GA        30350
                               Suite
        Cincinnati             Chiquita Center - Suite #700, 250 E.   Cincinnati       OH        45202
                               Fifth
        Fairfield              Greenbrook Corporate Center, 100       Fairfield        NJ        07004
                               Passi
        Fort Washington        500 Office Center Drive                Fort Washington  PA        19034
        Los Angeles            200 North Sepulveda Blvd., Suite #800  El Segundo       CA        90245
        Bentonville            805 McClain Rd.                        Bentonville      AZ        72712
        Minneapolis            7650 Edinborough Way, Suite #650       Edina            MN        55435
        Norwalk                383 Main Avenue                        Norwalk          CT        06851
        San Francisco          525 Market Street, 24th Floor          San Francisco    CA        94105
        Waltham                1601 Trapelo Road                      Waltham          MA        02451
        Winston-Salem, N.C.    150 South Stratford Road, Suite #530   Winston-Salem    NC        27103
        Toronto                4711 Yonge Street                      North York       Ontario   M2N 6K8
</TABLE>

        B'SCAN MARKETS 1/1/2001

<TABLE>
<CAPTION>
        OFFICE LOCATION        STREET ADDRESS                         CITY             STATE     ZIP
<S>                            <C>                                    <C>              <C>       <C>
        #10 Cedar Rapids       819 Fifth Street, S.E.                 Cedar Rapids     IA        52401
        #3 Eau Claire          3540 Jeffers Road                      Eau Claire       WI        54703
        #7 Grand Junction      Solarus Square, 2829 North Avenue      Grand Junction   CO        81501
        #4 Midland             15 Byron Road                          Midland          TX        79703
        #1 Pittsifeld          631 North Street                       Pittsfield       MA        01201
        #1 Visalia             2043 South Court Street                Visalia          CA        93277
</TABLE>

        B'SCAN STUDIOS 1/1/2001

<TABLE>
<CAPTION>
        OFFICE LOCATION        STREET ADDRESS                         CITY             STATE     ZIP
<S>                            <C>                                    <C>              <C>       <C>
        Cedar Rapids           6300 Council St., N.E., Suite #8       Cedar Rapids     IA        52402
        Eau Claire             1040 Mary Lane                         Eau Claire       WI        54703
        Midland                2528 South Midkiff Avenue              Midland          TX        79701
        Pittsfield             4 Fredrico Drive, Suite #C             Pittsfield       MA        01201
</TABLE>
<PAGE>
                                   SCHEDULE B

                         REAL ESTATE LEGAL DESCRIPTIONS

                                    --NONE--
<PAGE>
                                   SCHEDULE C

                        INVESTMENT PROPERTY AND DEPOSITS

A.    Investment Property
      Cantor Fitzgerald a/c # 350000833 (Information Resources, Inc. security
      account)
      Account is primarily used to repurchase company stock (ticker symbol
      "IRIC")
      Current account balance is $0

      Tucker Anthony a/c # DTM-953409-1 (Information Resources, Inc. security
      account)
      Account is primarily used to repurchase company stock (ticker symbol
      "IRIC")
      Current account balance is $0

      See attached for listing of current subsidiary and JV interests.

B.    Deposits
      Harris Bank a/c # 294-009-6 (Information Resources, Inc. depository
      account)
      Harris Bank a/c # 294-003-9 (Information Resources, Inc. French
      Holdings)
      Harris Bank a/c # 294-019-5 (Information Resources, Inc. Venezuela
      Holdings)
      Harris Bank a/c # 294-077-3 (Information Resources, Inc. Hellas SA)
<PAGE>
                                                             AS OF OCTOBER, 2001

                           INFORMATION RESOURCES, INC.
                       LIST OF SUBSIDIARIES AND AFFILIATES

<TABLE>
<CAPTION>
                                                     JURISDICTION                   PERCENTAGE
DOMESTIC                                             OF INCORPORATION               OWNERSHIP
--------                                             ----------------               ---------
<S>                                                  <C>                            <C>
IRI Logistics, Inc. (formerly                        Delaware                          100%
  LogiCNet, Inc.) *
IRI Puerto Rico, Inc. (formerly                      Puerto Rico                       100%
  Market Trends, Inc.)
Mosaic InfoForce, L.P.                               Delaware                           49%
Shoppers Hotline, Inc.                               Delaware                          100%
North Clinton Corporation                            Illinois                          100%
564 Randolph Co. #2                                  Illinois                          100%
IRI French Holdings, Inc. ***                        Delaware                          100%
IRI Italy Holdings, Inc. ***                         Delaware                          100%
InfoScan Italy Holdings, Inc. ***                    Delaware                          100%
IRI Venezuela Holdings, Inc. ***                     Delaware                          100%
IRI Guatemala Holdings, Inc. ***                     Delaware                          100%
IRI Greek Holdings, Inc. ***                         Delaware                          100%
</TABLE>

 *    Inactive
***   Holding companies for IRI's interest in foreign companies and joint
      ventures

                                      -2-
<PAGE>
                           INFORMATION RESOURCES, INC.
                  LIST OF SUBSIDIARIES AND AFFILIATES (CONT'D)

FOREIGN (including Joint Venture Subsidiaries)

<TABLE>
<CAPTION>
FOREIGN SUBSIDIARIES
OWNERSHIP                                            JURISDICTION OF INCORPORATION           PERCENTAGE
---------                                            -----------------------------           ----------
<S>                                                  <C>                                     <C>
Information Resources, S.A *                         France                                  100%
IRI Software, Ltd. (formerly Management
   Decision Systems, Limited) *                      United Kingdom                          100%
Information Resources, GmbH *                        Federal Republic of Germany             100% (thru IRI
                                                                                              Software B.V)
Information Resources New Zealand *
  Pty Limited                                        New Zealand                             100%
Information Resources de Mexico, S.A. de C.V. *      Mexico                                  100%
IRI Hellas S.A.  +                                   Greece                                  100% (thru IRI Greek
                                                                                               Holding)
IRI InfoScan S.r.l.   +                              Italy                                   100% (80% thru IRI
                                                                                             Italy and 20% thru
                                                                                             InfoScan Italy Hdg)

IRI Software B.V. *                                  Holland                                 100%

Precis (1136) Limited                                United Kingdom                          Approx. 95%

IRI Apollo K.K. *                                    Japan                                   100%
</TABLE>

*  Software Sales offices
+  Information business

                                      -3-
<PAGE>
                           INFORMATION RESOURCES, INC.
                       LIST OF SUBSIDIARIES AND AFFILIATES (CONT'D)

FOREIGN (Cont'd)

<TABLE>
<CAPTION>
FOREIGN JOINT VENTURES
OWNERSHIP                                            JURISDICTION OF INCORPORATION           PERCENTAGE
---------                                            -----------------------------           ----------
<S>                                                  <C>                                     <C>
IRI-SECODIP, S.C.S  +                                France                                  92%

IRI InfoScan Limited  +                              United Kingdom                          Approx. 87%
  (formerly InfoScan NMRA)                                                                     thru Precis 1136

Radar Retail Research +                              United Kingdom                          Approx. 35% thru
                                                                                               IRI InfoScan (UK)

IRI/GfK Retail Services GmbH +                       Federal Republic of Germany             Approx. 60% as of
                                                                                               9/00
Information Resources-GfK B.V.  +
(formerly IRI/GfK Retail Services B.V
and before that known as GfK InfoScan B.V.)                   Netherlands                    80.1%

Information Resources Espana, S.L. +                          Spain                          Approx. 65% as of
                                                                                               9/00

GfK Panelservices Benelux B.V +                               Netherlands                    10%
  (formerly AGB Atwood Hold. B.V. and
   now holding co. for  the one Belgium and
   three Netherland companies below)

Datos Information Resources   +                               Venezuela                      49% (thru IRI
                                                                                               Venez. Holdings)

Grupo de Servicios de Informacion S.A. +                      Guatemala                      19.9% (thru IRI
                                                                                               Guat. Holdings w/
                                                                                               option to increase
                                                                                               to 49% over time)
</TABLE>

                                      -4-
<PAGE>
<TABLE>
<CAPTION>
FOREIGN JOINT VENTURES
OWNERSHIP                                            JURISDICTION OF INCORPORATION           PERCENTAGE
---------                                            -----------------------------           ----------
<S>                                                  <C>                                     <C>
GfK InfoScan Sverige AB +/++                                  Sweden                         8%
(formerly named GfK Scannerinformation Sverige)

MEMRB International Limited (Cyprus) +                        Cyprus                         Approx.

Information Resources Japan, Ltd. +                           Japan                          40% (thru IRI
                                                                                               Apollo KK)

Trigent Software                                              India                          less than 5%
</TABLE>

*  Software Sales offices
+  Information business
++ Certain assets of Swedish venture were sold to Nielsen

                                      -5-<PAGE>

                                                                    Exhibit 10.1

                              DATED 31 AUGUST 2001

                                CIMA LABS INC (1)

                                       AND

                           ASTRAZENECA UK LIMITED (2)

                                SUPPLY AGREEMENT

IN RELATION TO [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***]
<PAGE>
                                                                    Exhibit 10.1

                                     INDEX

1.       INTERPRETATIONS AND DEFINITIONS
2.       DURATION
3.       SALE AND PURCHASE
4.       FORECASTING AND ORDERING
5.       DELIVERY AND TITLE
6.       PRICE
7.       PAYMENT
8.       WARRANTIES & QUALITY OF THE PRODUCT
9.       ASTRAZENECA'S IVRS
10.      REGULATORY REQUIREMENTS
11.      FORCE MAJEURE
12.      HARDSHIP
13.      TERMINATION
14.      COMPETITION
15.      MOST FAVOURED CUSTOMER
16.      CONFIDENTIALITY
17.      PROVISION OF TECHNOLOGY & IMPROVEMENTS
18.      ANNOUNCEMENTS/PUBLICITY
19.      NOTICES
20.      AGENCY, PARTNERSHIP OR JOINT VENTURE EXCLUDED
21.      NON-ASSIGNMENT
22.      ENTIRE AGREEMENT
23.      REMEDIES AND WAIVERS
24.      SEVERABILITY/INVALIDITY
25.      VARIATIONS AND/OR AMENDMENTS
26.      LAW AND JURISDICTION
27.      COUNTERPARTS
SCHEDULE 1 : PRODUCT SPECIFICATION
SCHEDULE 2 : PACKING SPECIFICATION
SCHEDULE 3 : STOCK REPORTING FORMAT
SCHEDULE 4 PRICE MATRIX
SCHEDULE 5 SUPPLY PARAMETERS

                                       2
<PAGE>
                                                                    Exhibit 10.1

SCHEDULE 6 SELF SUPPLY TERMS

                                       3
<PAGE>
                                                                    Exhibit 10.1

THIS AGREEMENT is dated 31st August 2001 and is made BETWEEN:

(1)      CIMA LABS INC., a Delaware corporation, whose principal office is at
         10000 Valley View Road, Eden Prairie, Minnesota, 55344,USA ("CIMA");
         and

(2)      ASTRAZENECA UK LIMITED (No. 03674842) a company incorporated in England
         and Wales whose registered office is at 15 Stanhope Gate, London W1K
         1LN ("AstraZeneca").

WHEREAS:

(A)      CIMA owns rights to certain oral drug delivery technology marketed
         under the trade mark DuraSolv(TM) and related know-how.

(B)      AstraZeneca has an exclusive licence to use and sell products
         containing the drug [***CONFIDENTIAL TREATMENT REQUESTED, PORTION
         OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.***].

(C)      CIMA and AstraZeneca have entered into a Development and Licence Option
         Agreement (the "Option Agreement") pursuant to which CIMA has granted
         AstraZeneca an exclusive licence dated 28 May 1999 (the "Licence
         Agreement") to use the DuraSolv(TM) technology in formulations with API
         (together, the "Product").

                                       4
<PAGE>
                                                                    Exhibit 10.1

(D)      In accordance with the general obligations of Clause 3.5 of the Option
         Agreement, CIMA wishes to manufacture, supply and AstraZeneca wishes to
         purchase Product and Placebo on the terms and conditions set out below
         (the "Agreement").

NOW IT IS HEREBY AGREED as follows:

1        INTERPRETATIONS AND DEFINITIONS

         1.1      HEADINGS AND DEFINITIONS

         In this Agreement, including its Schedules, the headings are included
         for ease of reference only and shall not affect its interpretation and,
         unless the context expressly requires otherwise:

                  1.1.1    "Affiliate" means, with respect to each party, any
                           corporation or other business entity that (a)
                           directly or indirectly controls, is owned by or is
                           under common ownership with a party to this Agreement
                           to the extent of at least fifty percent (50%) of the
                           equity (or such lesser percentage which is the
                           maximum allowed to be owned by a foreign organisation
                           in a particular jurisdiction) having the power to
                           vote or direct the affairs or such entity, or (b)
                           directly or indirectly Controls, is Controlled by or
                           is under common Control with such party;

                  1.1.2    "Associated Company" means any company which is
                           either the parent undertaking or a subsidiary
                           undertaking of the party in question or a subsidiary
                           undertaking of such party's parent undertaking and an

                                       5
<PAGE>
                                                                    Exhibit 10.1

                           undertaking in which the party in question has a
                           participating interest (as defined in section 260
                           Companies Act 1985) and which is not a subsidiary
                           undertaking of the party in question. "Parent
                           undertaking" and "subsidiary undertaking" shall have
                           the meanings attributed thereto in section 258
                           Companies Act 1985;

                  1.1.3    "Business Day" means a day (other than a Saturday,
                           Sunday or Bank Holiday) on which banks are open for
                           the transaction of normal business in the City of
                           London;

                  1.1.4    "Calendar Quarter" means each successive period of
                           three calendar months commencing in each Calendar
                           Year on 1st January, 1st April, 1st July and 1st
                           October and referred to as Q1, Q2, Q3 and Q4
                           respectively;

                  1.1.5    "Calendar Year" means each successive period of
                           twelve calendar months commencing on 1st January;

                  1.1.6    "Certificate of Analysis" means the certificate of
                           analysis to accompany all Product delivered to
                           AstraZeneca in the agreed format;

                  1.1.7    "Commercial Phase" means from [***CONFIDENTIAL
                           TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
                           WITH THE SECURITIES AND EXCHANGE COMMISSION.***] to
                           the date of termination of this Agreement;

                                       6
<PAGE>
                                                                    Exhibit 10.1

                  1.1.8    "manufacture of Product" means storage, checking and
                           testing of both incoming materials and outgoing
                           Product, processing and blister packing of tablets
                           with overprinted lidding into pre-formed strips of
                           multiples of 6 or 2 tablets per strip which are then
                           bulk packed in an agreed container ready for
                           shipment. It is agreed between the parties that this
                           definition complies with the description 'bulk
                           unlabelled and unpacked blisters' in Exhibit I of the
                           Development and Licence Agreement as far as pricing
                           is concerned .In such description it is acknowledged
                           that unlabelled allows for provision of certain
                           variable Product information and packing instructions
                           and that if AstraZeneca wishes CIMA to provide
                           Product in non standard packaging (cassettes) prior
                           to bulk packing, additional costs shall be incurred;

                  1.1.9    "Manufacturing Quarter" means the calendar quarter in
                           which product or placebo is manufactured but which is
                           cleared for delivery within the 15 days following
                           that calendar quarter;

                  1.1.10   "Placebo" means formulations made using CIMA's
                           DuraSolv(TM) Technology but without the inclusion of
                           API. Manufacture of Placebos shall mean the same as
                           manufacture of Product but in addition Placebos are
                           to be supplied packed in cartons prior to being
                           packed into an agreed container ready for shipment.
                           It is agreed between the parties that this definition
                           complies with the description for 'Finished Packaged
                           Product' in Exhibit 1 of the Development and Licence
                           Agreement in relation to

                                       7
<PAGE>
                                                                    Exhibit 10.1

                           pricing;

                  1.1.11   "Quality Assurance Agreements" mean the quality
                           assurance agreement signed by the parties and dated
                           23rd April 1999 and the US quality assurance
                           agreement signed by the parties dated April 11, 2000;

                  1.1.12   "Product" means any pharmaceutical dosage form which
                           is formulated using the DuraSolv(TM) Technology and
                           which contains [***CONFIDENTIAL TREATMENT REQUESTED,
                           PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES
                           AND EXCHANGE COMMISSION.***] as its active
                           ingredient, whether taste masked (in any flavour ) or
                           untreated;

                  1.1.13   "Product Specification" means the specification for
                           the Product as specified in Schedule 1 and as amended
                           from time to time by agreement in writing between the
                           parties;

                  1.1.14   "Pre-printed Foil" means forming and lidding foil
                           purchased by CIMA for exclusive use in the
                           manufacture of particular market variants of Product;

                  1.1.15   "Packing Specification" means the specification for
                           Placebo and Product ready for delivery to
                           AstraZeneca;

         1.2      DEFINITIONS

                  Unless expressly stated otherwise in clause 1.1 above,
                  capitalised terms shall

                                       8
<PAGE>
                                                                    Exhibit 10.1

                  bear the meaning ascribed to them in the Licence Agreement.

         1.3      COMPANY

                  References to a "company" shall be construed so as to include
                  any company, corporation or other body corporate wherever and
                  however incorporated or established.

         1.4      CONTROL

                  For the purposes of this Agreement a person is to be taken as
                  having "Control" of a company if:

                  1.4.1    the directors of the company or of another company
                           which has control of it (or any of them) are
                           accustomed to act in accordance with his directions
                           or instructions; or

                  1.4.2    either alone or with any one or more associates he is
                           entitled to exercise, or directly influence the
                           exercise of, one third or more of the voting power at
                           any general meeting of the company or of another
                           company which has control of it; or

                  1.4.3    he is otherwise able to secure by any voting or other
                           powers conferred by the articles of association or
                           other document regulating that or any other company
                           that the affairs of the company are conducted in
                           accordance with his wishes,

                                       9
<PAGE>
                                                                    Exhibit 10.1

and where two or more persons together satisfy any of the above conditions, they
are to be taken as having control of the company.

         1.5      PERSONS

                  The word "person" and words importing persons shall be
                  construed so as to include individuals, firms, bodies
                  corporate, joint ventures, governments, states or agencies of
                  state (whether or not having separate legal personality).

         1.6      SUCCESSORS AND ASSIGNEES

                  A reference to any party to this Agreement shall include a
                  reference to its legal successors and permitted assignees.

         1.7      GENDER

                  References to any of the masculine, feminine or neuter genders
                  shall include the other genders and references to the singular
                  number shall include the plural and vice versa if the context
                  so requires.

         1.8      REFERENCES

                  Unless the context expressly requires otherwise, references to
                  recitals, clauses, paragraphs, parties and Schedules are to
                  the recitals, clauses and paragraphs of and the parties and
                  Schedules to this Agreement. To the extent that there is
                  conflict between or ambiguity relating to, on the one hand,
                  any or all of the Schedules and, on the other, the remainder
                  of this Agreement, the wording of the Schedules shall prevail.

                                       10
<PAGE>
                                                                    Exhibit 10.1

         1.9      SCHEDULES

                  The Schedules and any attachments form part of this Agreement
                  and shall have the same force and effect as if expressly set
                  out in the body of this Agreement and any reference to this
                  Agreement shall include the Schedules and any attachments.

         1.10     LEGAL TERMS

                  References to any English term for any action, remedy, method
                  of judicial proceeding, legal document, legal status, court,
                  official or any legal concept or thing shall in respect of any
                  jurisdiction other than England be deemed to include what most
                  nearly approximates in that jurisdiction to the English legal
                  term.

         1.11     DATES AND TIMES

                  Reference to a date or time is a reference to that date or
                  time in London, England, unless expressly stated otherwise.

         1.12     WRITING

                  References to writing shall include any mode of reproducing
                  words in a legible and non-transitory form.

2        TERM AND TERMINATION

         2.1      TERM

                  This Agreement will be coterminous with the Licence Agreement
                  and as such will be effective as of the date hereof and will
                  expire on a country by country basis,

                                       11
<PAGE>
                                                                    Exhibit 10.1

                  upon the later date of (a) ten (10) years after the date of
                  first commercial sale of the Product in the relevant country,
                  or (b) the expiration of the last Patent covering the Product
                  filed in that country. The parties will meet in good faith
                  jointly to consider ways to extend this Agreement to the
                  extent permitted by applicable law or regulation at least
                  [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
                  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***]
                  before this Agreement is due to terminate pursuant to this
                  clause 2.1 and the parties may so extend the term in a writing
                  signed by both parties.

         2.2      TERMINATION

                  2.2.1    AstraZeneca may terminate this Agreement in its
                           entirety or with respect to use of the rights
                           licensed in any country or countries under the
                           Licence Agreement, with or without cause, upon
                           [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                           FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                           COMMISSION.***] written notice to CIMA. Such
                           termination will not relieve AstraZeneca or any
                           obligation to make payments to CIMA for royalties
                           accrued prior to the effective date of such
                           termination. AstraZeneca may sell, transfer or
                           otherwise dispose of for payment any of the Product
                           that is not sold prior to the effective date of such
                           termination, so long as such sale, transfer or
                           disposal occurs within three months of the effective
                           date of termination of this Agreement.

                                       12
<PAGE>
                                                                    Exhibit 10.1

                  2.2.2    Either party may terminate this Agreement prior to
                           its expiration by giving written notice to the other
                           party, if the other party materially fails or
                           neglects to perform its obligations under this
                           Agreement and the same is not cured or being cured to
                           the non-breaching party's reasonable satisfaction
                           within forty five (45) days after the non-breaching
                           party gives written notice specifying the nature and
                           extent of such material breach; provided, however,
                           that CIMA may not assert a material payment default
                           by AstraZeneca on invoiced amounts disputed in good
                           faith by AstraZeneca if AstraZeneca provides a
                           written description of the disputed amounts to CIMA.
                           Cure of a material payment default by AstraZeneca
                           will be made by remitting to CIMA the amount of the
                           overdue payment with accrued interest thereon,
                           calculated using a major US commercial bank rate
                           selected by CIMA, during the forty-five day period.

                  2.2.3    This Agreement shall terminate at the same time as
                           the termination (for whatever reason) of the Licence
                           Agreement and any notice to terminate served under
                           the terms of the Licence Agreement shall be deemed
                           also to be a notice to terminate this Agreement.

                  2.2.4    Either party may terminate this Agreement immediately
                           and without notice in the event that an application
                           is made by the other party for the appointment of a
                           receiver, trustee or custodian for any of the other
                           party's assets; a petition under any section or
                           chapter of the federal Bankruptcy Code or any similar
                           law or regulation of the United States or Puerto Rico
                           or the United Kingdom is filed by or against the
                           other party is not

                                       13
<PAGE>
                                                                    Exhibit 10.1

                           dismissed within sixty (60) days; the other party
                           makes an assignment for the benefit of its creditors;
                           the other party becomes insolvent or fails generally
                           to pay its debts when they come due; or if Control of
                           the other party passes to any persons who do not on
                           the Effective Date Control that party provided,
                           however, that such change in Control would result in
                           an unreasonable competitive situation for the party
                           claiming a right to terminate.

                  2.2.5    If AstraZeneca terminates this Agreement other than
                           under Sections 2.2.1 or 2.2.2, or if CIMA terminates
                           this Agreement under Section 2.2.2, then AstraZeneca
                           will pay to CIMA the amounts set out in clause 9.2(d)
                           of the Licence Agreement.

                  2.2.6    CIMA may terminate this Agreement upon
                           [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                           FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                           COMMISSION.***] notice in the event that AstraZeneca
                           or its Affiliates commercialise under any agreement
                           with a third party a formulation of [***CONFIDENTIAL
                           TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
                           WITH THE SECURITIES AND EXCHANGE COMMISSION.***].
                           This restriction on AstraZeneca and its Affiliates is
                           subject to the right of AstraZeneca to self-supply
                           the Product under Section 3.2 of this Agreement.

                                       14
<PAGE>
                                                                    Exhibit 10.1

         2.3      ADDITIONAL REMEDIES

                  Termination of this Agreement for any reason will be without
                  prejudice to, and will not affect the right of, either party
                  to recover any and all damages to which it may be entitled, or
                  to exercise any other remedies that it may otherwise have.

         2.4      SURVIVAL

                  Clauses 10, 12, 13, 17, 18, 19, 20, 21, 22, 23, 24 and 26
                  shall survive the termination of this Agreement howsoever the
                  same occurs.

3        SALE AND PURCHASE

         3.1      Except under the conditions of clause 3.2 of this Agreement,
                  CIMA shall manufacture and supply all quantities of the
                  Product and Placebo required by AstraZeneca and within the
                  forecast limitations set forth in clause 5 of this Agreement
                  and AstraZeneca shall purchase all quantities of the Product
                  and Placebo during the Validation Phase and the Commercial
                  Phase from CIMA upon the terms of this Agreement and in
                  accordance with the provisions of the Quality Assurance
                  Agreement (as amended from time to time). In the event that
                  there is a conflict between the terms of this Agreement and
                  the terms of Quality Assurance Agreements, the terms of this
                  Agreement shall prevail.

         3.2      As described more particularly in Schedule 6 of this
                  Agreement, CIMA shall grant AstraZeneca a self supply option
                  for Product. The payments to be made by AstraZeneca to CIMA
                  under the terms of Schedule 6 shall be the only payments made
                  in relation to the self supply option and shall cover all
                  future strengths and

                                       15
<PAGE>
                                                                    Exhibit 10.1

                  dosage forms of the Product.

         3.3      Supply of quantities of Product substantially greater than
                  [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
                  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***]
                  tablets per calendar year may require investment on the part
                  of CIMA. Such quantities should be forecast in writing by
                  AstraZeneca no later than [***CONFIDENTIAL TREATMENT
                  REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
                  SECURITIES AND EXCHANGE COMMISSION.***] prior to the date on
                  which AstraZeneca requires delivery of such quantity to
                  commence.

4        OBLIGATIONS IN RELATION TO MANUFACTURING AND SUPPLY STANDARDS

         4.1      CIMA undertakes to obtain and maintain all permits,
                  registrations and licences necessary for its equipment,
                  facilities and resources to be used to manufacture Placebo and
                  Product that meets the agreed Specification in accordance with
                  the terms of the Quality Assurance Agreement using purchased
                  excipients and Pre-printed Foil.

         4.2      CIMA shall hold agreed Safety Stock as described in Clause 7
                  and 8.

         4.3      CIMA shall provide AstraZeneca with a Certificate of Analysis
                  and agreed campaign documentation no later than
                  [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
                  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***]
                  (except in relation to Product

                                       16
<PAGE>
                                                                    Exhibit 10.1

                  under investigation by CIMA) after completion of blister
                  packing to initiate collection of Product by AstraZeneca. In
                  addition, fully signed manufacturing campaign validation
                  reports shall be provided by CIMA before the expiry of the
                  period stipulated in the relevant validation protocol.

         4.4      CIMA may employ a third party to test Product in whole or in
                  part, provided that such third party is approved by
                  AstraZeneca and that such party agrees to be bound by the
                  terms of the Quality Assurance Agreement. CIMA shall bear the
                  full liability for such third party costs.

         4.5      If revised manufacturing standards or revised Product
                  specifications are required which result in an increased cost
                  of production to CIMA, and which relate specifically to the
                  Product:

                  4.5.1    as a result of requests by external regulatory
                           bodies, the Parties shall discuss and agree on an
                           implementation plan to achieve such revisions within
                           thirty days of the revisions being known to both
                           Parties. AstraZeneca shall either bear the cost of
                           goods increases agreed or exercise its right to
                           self-supply described in clause 3.2 above;

                  4.5.2    as a result of a request by AstraZeneca, the Parties
                           shall discuss and agree an implementation plan to
                           achieve such revisions for which AstraZeneca shall
                           bear the cost in full on terms to be agreed;

                                       17
<PAGE>
                                                                    Exhibit 10.1

                  4.5.3    it is understood by the Parties that this clause 4
                           does not apply to failures by CIMA to meet the
                           existing standards and specifications.

         4.6      AstraZeneca shall provide forecasts and orders in accordance
                  with the terms of this Agreement and shall provide design and
                  text for variable Product information to CIMA no later than
                  [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
                  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***] in
                  advance of scheduled use by CIMA.

         4.7      AstraZeneca shall provide API to CIMA for use solely in the
                  manufacture of Product in accordance with Clause 7.

         4.8      AstraZeneca shall collect Product from CIMA's manufacturing
                  facility promptly after the provision by CIMA of agreed
                  documentation as described in Clause 4.3 and AstraZeneca shall
                  inspect the Product on arrival at AstraZeneca's user
                  facilities in accordance with its obligations under the
                  Quality Assurance Agreement.

         4.9      Each party shall inform the other party without delay of
                  receipt of notice of any impending or threatened litigation or
                  governmental investigation or impending audit of any kind that
                  is or could be related to the manufacture of Product.

                                       18
<PAGE>
                                                                    Exhibit 10.1

5        FORECASTING AND ORDERING

         5.1      During the Commercial Phase the following shall apply:

                  5.1.1    Prior to 30th October in each Calendar Year,
                           AstraZeneca shall provide CIMA with a forecast ("THE
                           ANNUAL FORECAST") of AstraZeneca's annual
                           requirements for the Product and Placebo for each
                           Calendar Quarter of the subsequent Calendar Year
                           which will be expressed in terms of formulation
                           batches, each formulation batch being not less than
                           equal to [***CONFIDENTIAL TREATMENT REQUESTED,
                           PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES
                           AND EXCHANGE COMMISSION.***] (a "BATCH").

                  5.1.2    In each Calendar Year after 2002, AstraZeneca shall
                           be obliged to purchase not less than [***CONFIDENTIAL
                           TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
                           WITH THE SECURITIES AND EXCHANGE COMMISSION.***] of
                           the Annual Forecast for Product and CIMA shall be
                           obliged to supply up to [***CONFIDENTIAL TREATMENT
                           REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
                           SECURITIES AND EXCHANGE COMMISSION.***] of the Annual
                           Forecast for Product prorated equally throughout the
                           year.

                  5.1.3    For the avoidance of doubt, CIMA shall not be obliged
                           at any time to supply more than [***CONFIDENTIAL
                           TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
                           WITH THE SECURITIES

                                       19
<PAGE>
                                                                    Exhibit 10.1

                           AND EXCHANGE COMMISSION.***] of the Annual Forecast
                           in 5.1.2 or more than [***CONFIDENTIAL TREATMENT
                           REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
                           SECURITIES AND EXCHANGE COMMISSION.***] tablets
                           (product plus placebo combined), whichever is the
                           smaller, in any given Calendar Year unless the
                           Parties agree otherwise.

                  5.1.4    In the event that AstraZeneca does forecast to
                           require more than such maximum quantity, CIMA shall
                           immediately notify AstraZeneca of its receipt of such
                           a forecast and CIMA is obliged to inform AstraZeneca
                           in writing within thirty (30) days of receipt of such
                           forecast what quantity (if any) above the maximum
                           forecast quantity CIMA is able to supply.

                  5.1.5    In order to assist CIMA's production planning,
                           AstraZeneca shall, at the end of each Calendar
                           Quarter provide to CIMA a non-binding update of
                           AstraZeneca's requirements for Product and Placebo
                           for the next fifteen calendar months, with the first
                           six (6) month-by-month and the remainder by quarter.

                  5.1.6    AstraZeneca shall place binding orders for the
                           Product and Placebo required in each Manufacturing
                           Quarter with CIMA not less than thirty (30) days
                           before the start of that Manufacturing Quarter.
                           Quantities of individual market variants of Product
                           required to be delivered in each calendar month of
                           that Calendar Quarter shall be provided by
                           AstraZeneca in the form of call-off/manufacturing
                           orders to be placed no

                                       20
<PAGE>
                                                                    Exhibit 10.1

                           later than one month prior to the start of the month
                           of delivery.

6        DELIVERY AND TITLE

         6.1      Unless otherwise agreed all quantities of the Product and
                  Placebo supplied pursuant to this Agreement shall be delivered
                  EXW, CIMA to load Product and Placebos on to collecting
                  vehicle at CIMA's risk, from CIMA's facility at Eden Prairie,
                  MN, USA (Incoterms 2000).

         6.2      Risk in respect of all Product and Placebo supplied to
                  AstraZeneca pursuant to this Agreement shall pass accordingly.
                  Title to all Product and Placebo supplied to AstraZeneca shall
                  at all times remain with AstraZeneca.

         6.3      API shall be delivered by AstraZeneca at AstraZeneca's expense
                  to CIMA's facility at 10000 Valley View Road, Eden Prairie, MN
                  55344 USA and AstraZeneca shall retain title to all deliveries
                  of API at all times. Risk shall pass with ownership and both
                  parties undertake to maintain adequate insurance cover.

7        API TO BE SUPPLIED TO CIMA

         7.1      All deliveries of API shall meet agreed API and package
                  specifications and be accompanied by a Certificate of Analysis
                  and with at least [***CONFIDENTIAL TREATMENT REQUESTED,
                  PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
                  EXCHANGE COMMISSION.***] of its agreed shelf life

                                       21
<PAGE>
                                                                    Exhibit 10.1

                  remaining.

         7.2      CIMA shall store API in conditions approved by AstraZeneca and
                  shall rotate stock held to eliminate shelf life losses.

         7.3      CIMA shall test and handle API consistent with information
                  provided by AstraZeneca and in compliance with local laws and
                  regulations.

         7.4      All API deliveries must meet CIMA approved packaging,
                  documentation and labelling; including certificate of
                  analysis; gross/tare/net weight and manufacturing lot number.
                  The quantities and timing of deliveries shall be as follows:

                  7.4.1    During the Commercial Phase the Parties shall ensure
                           that a safety stock of API is maintained (the "API
                           Safety Stock") equivalent to [***CONFIDENTIAL
                           TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
                           WITH THE SECURITIES AND EXCHANGE COMMISSION.***] of
                           the Annual Forecast of Product (provided by
                           AstraZeneca on 30th October each Calendar Year)
                           multiplied by the agreed conversion ratio of
                           [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                           FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                           COMMISSION.***]. CIMA shall provide AstraZeneca at
                           the time of the monthly Stock Report described in
                           Clause 9 with the date that AstraZeneca needs to
                           deliver stock replenishment material in quantities
                           not less than [***CONFIDENTIAL TREATMENT

                                       22
<PAGE>
                                                                    Exhibit 10.1

                           REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
                           SECURITIES AND EXCHANGE COMMISSION.***]. Such
                           forecast delivery date shall not be less than 1 month
                           after the month that the stock report is issued to
                           AstraZeneca.

                  7.4.2    It is recognised by the parties that if AstraZeneca's
                           actual requirements vary substantially within the
                           allowed limits of Clause 5.1.2 and 5.1.4, that
                           adjustments may be needed to the API Safety Stock
                           level described in Clause 7.4.1 above. In such an
                           event, CIMA shall notify AstraZeneca at the time of
                           the monthly Stock Report that a new API Safety Stock
                           level is required and recommend new deliveries of API
                           that are required.

         7.5      During the Commercial Phase CIMA shall consume API at the rate
                  of [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
                  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***]
                  Batch .API consumed in excess of this rate shall be replaced
                  by AstraZeneca but at the expense of CIMA based on an API
                  price of USD [***CONFIDENTIAL TREATMENT REQUESTED, PORTION
                  OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                  COMMISSION.***]. CIMA shall provide a breakdown in writing of
                  any amounts due and shall make payment due in a Calendar Year
                  within 30 days after the end of that Calendar Year as part of
                  the reconciliation described in Clause 11.

8        PRE-PRINTED FOILS AT CIMA

                                       23
<PAGE>
                                                                    Exhibit 10.1

         8.1      Some markets for the Product require Pre-printed Lidding Foil
                  ("Pre-printed Lidding Foil"). AstraZeneca shall supply to CIMA
                  its design and text for the Pre-printed Lidding Foil for such
                  markets at least three (3) months in advance of CIMA's
                  manufacture of the Product for such markets. The cost for the
                  Pre-printed Lidding Foil has not been included in the costing
                  on Schedule 4. CIMA agrees to provide and AstraZeneca agrees
                  to pay [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                  FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                  COMMISSION.***] per tablet for all Product manufactured using
                  the Pre-printed Lidding Foil. This additional cost will be
                  billed to AstraZeneca in addition to the costs on Schedule 4.

9        STOCK REPORTING

         9.1      CIMA shall provide a stock report at the end of each calendar
                  month in the format as attached in Schedule 3 relating to API
                  stock holding and performance against agreed conversion ratios
                  as described in Clause 7.6 (the "Stock Report").

         9.2      In addition CIMA at the time of the report

                  (a) will recommend adjustments to API Safety Stock levels and
                  request stock replenishment quantities of API from AstraZeneca
                  as described in Clauses 7.4.2; and

                  (b) will recommend adjustments to Pre-printed Foil Safety
                  Stock levels

                                       24
<PAGE>
                                                                    Exhibit 10.1

                  both for confirmation by AstraZeneca within [5] working days.

10       PRICE

         10.1     All sums payable by AstraZeneca under this Agreement are
                  exclusive of Value Added Tax which, if payable, shall be borne
                  and paid by AstraZeneca upon the provision by CIMA of an
                  appropriate VAT invoice.

         10.2     The price to be paid by AstraZeneca for Product and Placebos
                  during the Commercial Phase will conform to the pricing in
                  Schedule 4.

         10.3     Subject to the exceptional circumstances set out in Clause 4.5
                  of this Agreement, the prices in Schedule 4 shall remain fixed
                  through [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                  FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                  COMMISSION.***]. On [***CONFIDENTIAL TREATMENT REQUESTED,
                  PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
                  EXCHANGE COMMISSION.***] and thereafter, the prices in
                  Schedule 4 shall be adjusted [***CONFIDENTIAL TREATMENT
                  REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
                  SECURITIES AND EXCHANGE COMMISSION.***].

                                       25
<PAGE>
                                                                    Exhibit 10.1

11       ORDER AND INVOICE PRICING AND RECONCILIATION

         11.1     During the Commercial Phase, Product and Placebo shall be
                  ordered and invoiced as follows:

                  11.1.1   In addition to the prices specified in Schedule 4 the
                           following surcharges shall apply,

                           [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                           FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                           COMMISSION.***]

                           cassette surcharge Pre-printed Lidding Foil surcharge

                           [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                           FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                           COMMISSION.***]

                           [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                           FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                           COMMISSION.***]

                           cassette surcharge Pre-printed Lidding Foil surcharge

                           [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                           FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                           COMMISSION.***]

                                       26
<PAGE>
                                                                    Exhibit 10.1

                  11.1.2   Within thirty days of the end of the first calendar
                           year CIMA shall debit or credit AstraZeneca with an
                           amount equal to the difference between the amount so
                           invoiced and the sum due with respect to the
                           aggregate of:

                           (a) Prices for Product as described in Schedule 4
                           that take account of cumulative batches and variants
                           actually ordered; and

                           (b) sums due in respect of performance against API
                           conversion ratio according to clause 7.5.

                  11.1.3   For each Calendar Year thereafter Placebos and the
                           cassette surcharge will continue to be used in orders
                           and invoices as described in Clause 11.1.2 but
                           Product will be ordered and invoiced at prices
                           according to Schedule 4 and where the cumulative
                           number of Batches of Product shall be taken as the
                           sum of the Batches of Product in the previous year
                           plus those Batches of Product forecast in
                           AstraZeneca's Annual Forecast for the year in
                           question and the number of variants forecast to be
                           ordered shall be taken as 5-12.

                  11.1.4   Within thirty days of the end of the calendar year
                           CIMA will debit or credit AstraZeneca with an amount
                           as described in clause 11.1.2.

12       PAYMENT

                                       27
<PAGE>
                                                                    Exhibit 10.1

         AstraZeneca shall pay all invoices in full in US Dollars by wire
         transfer to CIMA's registered office at Eden Prairie, Minnesota no
         later than 30 days following receipt of invoice (by fax or otherwise)
         subject to CIMA complying with its obligations under clause 4.3 of this
         Agreement.

13       WARRANTIES, QUALITY OF THE PRODUCT AND LIABILITY

         13.1     CIMA hereby warrants and undertakes to AstraZeneca that:

                  13.1.1   the performance by CIMA of its obligations to
                           AstraZeneca hereunder will not breach any covenant or
                           obligation of CIMA to any third party, or infringe
                           any rights of any third party; CIMA is not aware of
                           any matter or impediment which would prevent CIMA
                           from performing or would restrict or hinder CIMA in
                           the performance of its obligations hereunder;

                  13.1.2   Product to be supplied to AstraZeneca pursuant to
                           this Agreement (and all associated packaging and
                           documentation) shall be manufactured, analysed and
                           supplied in accordance with the provisions of Clause
                           4 which are summarised in Schedule 5 as supply
                           parameters (the "Supply Parameters").

         13.2     CIMA will inform AstraZeneca promptly in writing of any event
                  which in the reasonable judgement of CIMA may adversely affect
                  the suitability of the Product for AstraZeneca's use.

                                       28
<PAGE>
                                                                    Exhibit 10.1

         13.3     AstraZeneca shall notify CIMA of any non-compliance with the
                  Supply Parameters within forty-five (45) days of AstraZeneca's
                  receipt of Product. If and to the extent that AstraZeneca has
                  failed to examine the Product in accordance with this clause
                  13.3 (or it has failed to so notify CIMA in accordance with
                  this clause 13.3) the relevant consignment of the Product
                  shall be deemed to have been accepted by AstraZeneca in
                  satisfactory condition in respect of all damage, shortage or
                  defects which would have been discovered upon such
                  examination.

         13.4     CIMA and AstraZeneca agree to make best endeavours to resolve
                  all claims made in accordance with Clause 13.3. If a dispute
                  arises between the parties in relation to such claims which
                  cannot be resolved by the parties within ninety(90) days of a
                  claim being notified by AstraZeneca pursuant to clause 13.3,
                  either party shall be entitled to require that the matter in
                  dispute be referred to an independent expert nominated by
                  agreement of the parties or, failing agreement, appointed by
                  [the President of the International Chamber of Commerce,
                  Paris] at the instigation of either party. Such referral shall
                  be solely for the purpose of establishing whether or not there
                  is any shortage, damage or defect (as the case may be) in
                  relation to the Supply Parameters. Save in the case of fraud
                  or manifest error the decision of such independent expert
                  shall be binding upon the parties. In the event that the
                  independent expert decides there was no shortage, damage or
                  defect, the costs of the independent expert shall be borne by
                  AstraZeneca. In all other circumstances, the costs of the
                  independent expert shall be borne by CIMA.

                                       29
<PAGE>
                                                                    Exhibit 10.1

         13.5     If AstraZeneca brings a claim against CIMA in respect of a
                  defect in any Product supplied or in any associated packaging
                  or documentation, CIMA's liability in respect of such claim
                  shall at AstraZeneca's option be limited to either:-

                  13.5.1   replacing the defective item at CIMA's expense; or at
                           AstraZeneca's sole discretion;

                  13.5.2   refunding to AstraZeneca the cost paid to CIMA by
                           AstraZeneca for such defective item.

         13.6     In the event of AstraZeneca bringing a claim against CIMA in
                  respect of a non-disclosed change (as described in the Quality
                  Assurance Agreement) CIMA shall be required to bear the cost
                  of any resulting validation of the change and the cost of
                  obtaining any necessary regulatory approvals or alternatively
                  (at AstraZeneca's option) reverting to the original form of
                  manufacture and bearing the cost of any recall of Product
                  necessitated by such non-disclosed change.

         13.7     In the event of direct loss or damage to AstraZeneca's
                  employees, agents or contractors; to AstraZeneca's property or
                  to the environment associated with production using the
                  Product (and excluding circumstances which have been caused
                  directly by API or the negligence of AstraZeneca or its
                  employees, agents or contractors) CIMA shall bear the full
                  cost of any such loss or damage PROVIDED THAT CIMA shall bear
                  no liability for special, indirect or consequential loss.

                                       30
<PAGE>
                                                                    Exhibit 10.1

         13.8     In the event of direct loss or damage to CIMA's employees,
                  agents or contractors; to CIMA's property or to the
                  environment arising out of its due performance of its
                  obligations under this Agreement (and excluding circumstances
                  which have been caused directly by the negligence of CIMA or
                  its employees, agents or contractors) AstraZeneca shall bear
                  the full cost of any such loss or damage PROVIDED THAT
                  AstraZeneca shall bear no liability for special, indirect or
                  consequential loss.

         13.9     CIMA UNDERTAKES NO OTHER WARRANTIES OF ANY KIND, EXPRESS OR
                  IMPLIED, AND EXPRESSLY DISCLAIMS ANY WARRANTY OF
                  MECHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY AND
                  ALL LIABILITY FOR SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES.

14       VENDOR PERFORMANCE

         CIMA shall comply with the Vendor Rating Scheme an indicative version
         of which is set out in Schedule 5 and shall use its best endeavours to
         maintain Division 1 status throughout the term of this Agreement.

15       FORCE MAJEURE

         15.1     Subject to clause 15.3, each party shall be released from its
                  obligations under this Agreement to the extent that its
                  performance hereunder is delayed, hindered or prevented by
                  circumstances which are not within its reasonable control,

                                       31
<PAGE>
                                                                    Exhibit 10.1

                  including, without limitation, acts or restraints of
                  governments or public authorities; war, revolution, riot or
                  civil commotion; strikes, lock-outs or other industrial
                  action; blockage or embargo; failure of supplies of power,
                  fuel, transport, equipment or other goods or services; and
                  explosion, fire, flood or natural disaster (a "Force Majeure
                  Event").

         15.2     The party affected by such circumstances shall, as soon as it
                  becomes aware of them, give full written particulars of them
                  to the other party, and shall use best endeavours to resume
                  full performance of its obligations under this Agreement
                  without delay, and pending such resumption shall use best
                  endeavours to facilitate any efforts that the other party may
                  make to procure an alternative method by which its obligations
                  under this Agreement may be performed. Furthermore, if, as a
                  result of a Force Majeure Event CIMA is unable to supply the
                  quantity of Product ordered by AstraZeneca or the quantity
                  which AstraZeneca would have ordered but for such
                  circumstances then:-

                  15.2.1   AstraZeneca shall be obliged to purchase such Product
                           as it has actually ordered but at the price which
                           would have applied under schedule 4 had CIMA been
                           able to supply and had AstraZeneca purchased the
                           quantities actually required by AstraZeneca; and

                  15.2.2   if such circumstances continue or are forecast to
                           continue for more than [***CONFIDENTIAL TREATMENT
                           REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
                           SECURITIES AND EXCHANGE COMMISSION.***], CIMA shall
                           use all reasonable endeavours to offer to

                                       32
<PAGE>
                                                                    Exhibit 10.1

                           AstraZeneca alternative capacity for Product (at
                           prices and on terms to be agreed) which can be
                           operable within a further [***CONFIDENTIAL TREATMENT
                           REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
                           SECURITIES AND EXCHANGE COMMISSION.***] to the
                           standards required by the Quality Assurance
                           Agreement; and

                  15.2.3   CIMA shall allocate all available capacity of Product
                           produced by CIMA proportionally as between CIMA,
                           AstraZeneca and other customers of CIMA and CIMA
                           shall be deemed to have supplied the Product ordered
                           or forecast for the purposes of calculating the price
                           of the Product.

         15.3     Neither party shall be entitled to relief under this clause 15
                  for any delay or failure in performing any of its payment
                  obligations under this Agreement.

         15.4     If a Force Majeure Event other than the supply of API prevails
                  for a continuous period in excess of [***CONFIDENTIAL
                  TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
                  SECURITIES AND EXCHANGE COMMISSION.***], the party entitled to
                  notification of such circumstances in accordance with clause
                  15.2 may, without prejudice to any other rights or remedies
                  which may be available to it, terminate this Agreement with
                  immediate effect by giving written notice of termination to
                  the other party.

         15.5     If AstraZeneca is notified of a Force Majeure Event, the
                  obligation upon AstraZeneca to purchase the Product from CIMA
                  in accordance with this

                                       33
<PAGE>
                                                                    Exhibit 10.1

                  Agreement shall be suspended for the duration of the force
                  majeure event.

16       HARDSHIP

         16.1     For so long as any circumstances prevail which prevent or
                  impede AstraZeneca from using or selling the Product and which
                  AstraZeneca cannot control by taking all measures which can
                  reasonably be expected then AstraZeneca shall not be obliged
                  to place any further orders for the Product notwithstanding
                  any other provision of this Agreement but shall be obliged to
                  purchase such quantities of Product as it has actually
                  ordered. If such circumstances prevail for a period of
                  [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
                  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***] or
                  more, AstraZeneca shall be entitled to terminate this
                  Agreement forthwith on written notice to CIMA PROVIDED THAT,
                  on or prior to such termination, AstraZeneca shall:

                  (i) purchase all Product actually ordered prior to the date of
                  termination at the price specified in Schedule 4 and

                  (ii) pay CIMA for the purchase value of Pre-printed Foil
                  Safety Stock it holds or has ordered solely for use in the
                  manufacture of Product; and

                  (iii) compensate CIMA for all reasonable costs and expenses
                  incurred by CIMA (including the costs of excipients and
                  packaging materials specific to AstraZeneca purchased or
                  manufactured by CIMA solely for use in the

                                       34
<PAGE>
                                                                    Exhibit 10.1

                  manufacture of Product) in order to comply with its
                  obligations to supply Product pursuant to this Agreement such
                  costs and expenses not to exceed the cost of manufacturing six
                  (6) months' Safety Stock based on the latest forecast.

17       CONFIDENTIALITY

         17.1     Subject to clause 18, any know-how or other information
                  proprietary to either party to this Agreement which is
                  disclosed by that party ("the Discloser") or on its behalf to
                  the other party ("Recipient") in connection with this
                  Agreement ("Confidential Information") shall remain the
                  property of the Discloser and shall not, without the prior
                  written consent of the Discloser, be disclosed to any third
                  party or used by the Recipient except for the performance of
                  the Recipient's obligations under this Agreement.

         17.2     The obligations of non-use and confidentiality contained in
                  this clause 17 shall not apply to any information which the
                  Recipient can reasonably demonstrate;

                  17.2.1   was already in the possession of the Recipient and at
                           the Recipient's free use and disposal or in the
                           public domain (through no fault of the Recipient)
                           prior to its disclosure by the Discloser hereunder;
                           or

                  17.2.2   is purchased or otherwise legally acquired by the
                           Recipient at any time from a third party having good
                           title thereto and the right to disclose the same; or

                                       35
<PAGE>
                                                                    Exhibit 10.1

                  17.2.3   comes into the public domain, otherwise than through
                           the fault of the Recipient; or

                  17.2.4   is independently generated by the Recipient without
                           any recourse or reference to the information
                           disclosed by the Discloser.

                  All documents supplied by either party to the other which
                  contain Confidential Information within the scope of this
                  clause 17 shall be promptly returned by the Recipient to the
                  Discloser upon the expiry or termination of this Agreement.
                  The obligations of each party under this clause shall survive
                  the expiry or termination of this Agreement provided that the
                  Recipient shall have the right to retain in its legal
                  department a single copy for archival purposes to ensure
                  compliance with the above obligations.

         17.3     In addition to the Confidential Information identified in
                  clause 17, each party shall treat as Confidential Information
                  all information which it receives or obtains relating to:

                  17.3.1   the contents of or negotiations relating to this
                           Agreement; and

                  17.3.2   the business and customers of the other party.

         17.4     Each of the parties may disclose Confidential Information to
                  its directors and employees and professional advisers who need
                  to know the Confidential Information, provided that each party
                  shall procure that prior to such disclosure

                                       36
<PAGE>
                                                                    Exhibit 10.1

                  each of those directors, employees and professional advisers
                  to whom Confidential Information is to be disclosed is made
                  aware of the confidentiality obligations herein contained and
                  undertakes to adhere to such terms of this Agreement as if he
                  were a party to it.

         17.5     Each party is entitled to disclose Confidential Information to
                  Associated Companies, provided that each party shall procure
                  that prior to such disclosure each of those Associated
                  Companies to which Confidential Information is to be disclosed
                  is made aware of the confidentiality obligations herein
                  contained and undertakes to adhere to such terms of this
                  Agreement as if it were a party to it.

         17.6     Nothing in this clause 17 shall preclude disclosure of any
                  Confidential Information required by any governmental or
                  regulatory authority or court entitled by law to disclosure of
                  the same including, for the avoidance of doubt, any
                  information required for disclosure under the Securities Act
                  of 1933 (as amended) or the Securities Exchange Act of 1934
                  (as amended) or in accordance with the regulations of any
                  recognised stock exchange, or which is required by law,
                  provided that the party concerned promptly notifies the other
                  party when such requirement to disclose has arisen.

18       ANNOUNCEMENTS/PUBLICITY

         18.1     Save as expressly permitted in clause 18.2 neither party shall
                  make any announcement about the transaction contemplated by
                  this Agreement without the

                                       37
<PAGE>
                                                                    Exhibit 10.1

                  prior written consent of the other party.

         18.2     If any announcement concerning the transaction contemplated by
                  this Agreement or any ancillary matter is required of a party
                  by law or any securities exchange or regulatory or
                  governmental body to which either party is subject, the
                  announcement shall be made only after informing the other
                  party as to the terms of and timetable for publication of any
                  such announcement (if such consultation is reasonably
                  practicable).

19       NOTICES

         19.1     All notices and other communications given or made in relation
                  to this Agreement;

                  19.1.1   shall be in English and in writing;

                  19.1.2   shall be delivered by hand or courier or sent by
                           facsimile;

                  19.1.3   shall be delivered or sent to the party concerned at
                           the relevant address or facsimile number, shown in
                           clause 19.2 subject to such amendments as may be
                           notified from time to time in accordance with this
                           clause by the relevant party to the other party by no
                           less than three (3) Business Days' notice; and

                                       38
<PAGE>
                                                                    Exhibit 10.1

                  19.1.4   shall be deemed to have been duly given or made if
                           addressed in the aforesaid manner:

                           19.1.4.1 if delivered by hand or courier, upon
                                    delivery; and

                           19.1.4.2 if sent by facsimile, when a complete and
                                    legible copy of the communication, has been
                                    received at the appropriate address,

                           provided that if any notice or other communication
                           would otherwise become effective on a non-Business
                           Day or after 5.00 p.m. on a Business Day, it shall
                           instead be deemed to be given or made at 10.00 a.m.
                           on the next Business Day.

         19.2     The initial details for the purposes of clause 19.1 are: For
                  AstraZeneca

                  Alderley House, Alderley Park

                  Macclesfield, Cheshire

                  SK10 4TF, England

                  Facsimile: 01625 514061

                  For the attention of: Supply Manager

                  For CIMA

                  10000 Valley View Road

                  Eden Prairie

                                       39
<PAGE>
                                                                    Exhibit 10.1

                  MN 55344

                  U.S.A.

                  Facsimile: 001 612 947 8770

                  For the attention of: President and Chief Executive Officer

20       AGENCY, PARTNERSHIP OR JOINT VENTURE EXCLUDED

         20.1     Nothing in this Agreement shall be construed so as to
                  constitute either party to be the agent of the other.

         20.2     Nothing in this Agreement and no action taken by the parties
                  pursuant to this Agreement shall constitute a partnership or
                  joint venture of any kind between the parties.

21       NON-ASSIGNMENT

         21.1     Save as hereinafter provided this Agreement shall not be
                  assigned nor any of the obligations hereunder transferred (nor
                  the performance of any obligation hereunder sub-contracted) by
                  either party except with the prior written consent of the
                  other, provided that no consent shall be required in the cases
                  of an assignment or transfer to an Associated Company of that
                  party provided that any such assignment shall be made on terms
                  that, should any such assignee cease to be an Associated
                  Company of the assignor then the Agreement and any obligations
                  which have been transferred to the assignee shall be
                  transferred

                                       40
<PAGE>
                                                                    Exhibit 10.1

                  back to the assignor.

22       ENTIRE AGREEMENT

         22.1     Each party acknowledges that in entering into this Agreement
                  it places no reliance on any representation or warranty
                  relating to the subject matter of this Agreement, save for the
                  representations and warranties expressly set out herein.

         22.2     Subject to any terms implied by law, this Agreement, the
                  Licence Agreement and the Quality Assurance Agreements
                  together represent the entire agreement between the parties in
                  relation to the subject matter of this Agreement and supersede
                  any previous agreement or arrangement, between the parties in
                  relation to that subject matter whether written or oral or
                  which might be inferred from the conduct of the parties.

23       REMEDIES AND WAIVERS

         23.1     No delay or omission on the part of either party in exercising
                  any right, power or remedy provided by law or under this
                  Agreement shall:-

                  23.1.1   impair such right, power or remedy; or

                  23.1.2   operate as a waiver thereof.

                                       41
<PAGE>
                                                                    Exhibit 10.1

         23.2     The single or partial exercise of any right, power or remedy
                  provided by law or under this Agreement shall not preclude any
                  other or further exercise thereof or the exercise of any other
                  right, power or remedy.

         23.3     The rights, powers and remedies provided in this Agreement are
                  cumulative and not exclusive of any rights, powers and
                  remedies provided by law.

24       SEVERABILITY/INVALIDITY

         24.1     Should any provision of this Agreement be held to be illegal,
                  invalid or unenforceable in any respect by any judicial or
                  other competent authority under the law of any jurisdiction:

                  24.1.1   such provision shall, so far as it is illegal,
                           invalid or unenforceable in any jurisdiction, be
                           given no effect by the parties and shall be deemed
                           not to be included in this Agreement in that
                           jurisdiction;

                  24.1.2   the other provisions of this Agreement shall be
                           binding on the parties in that jurisdiction as if
                           such provision were not included herein;

                  24.1.3   the legality, validity and enforceability of the
                           provision in any other jurisdiction shall not be
                           affected or impaired; and

                  24.1.4   the parties agree to negotiate in good faith to amend
                           such provision to the extent possible for
                           incorporation herein in such reasonable manner as

                                       42
<PAGE>
                                                                    EXHIBIT 10.1

                           most closely achieves the intention of the parties
                           and without rendering such provision invalid or
                           unenforceable.

25       VARIATIONS AND/OR AMENDMENTS

         25.1     This Agreement may only be varied or amended by agreement in
                  writing signed by or on behalf of the parties.

26       LAW AND JURISDICTION

         26.1     This Agreement shall be governed by, interpreted and enforced
                  in accordance with the laws of the State of Delaware, without
                  regard to its choice of law provisions.

         26.2     The parties will use all reasonable efforts to resolve in an
                  amicable fashion any dispute, claim or controversy that may
                  arise relating to the terms or performance of this Agreement.
                  If the parties are unable to resolve such dispute within
                  thirty (30) days after initial notice, either party may, by
                  notice to the other, have such dispute referred to a senior
                  officer of each company. Such officers shall attempt to
                  resolve the dispute by good faith negotiation within thirty
                  (30) days after receipt of such notice. If the designated
                  officers are not able to resolve such dispute within ninety
                  (90) days after receipt of such notice, the parties will
                  submit the dispute to arbitration by a single arbitrator in
                  Minneapolis, Minnesota, in accordance with the Commercial
                  Arbitration Rules of the American Arbitration Association then
                  in effect. The arbitrator must be a retired judge of a state
                  or federal court of the United States or a licensed lawyer
                  with at least ten (10) years

                                       43
<PAGE>
                                                                    EXHIBIT 10.1

                  of intellectual property law experience from a law firm with
                  at least ten (10) attorneys and at least an AV rating by
                  Martindale Hubbell. A list of ten (10) potential arbitrators
                  shall be obtained from the AAA. Each party to the dispute will
                  rank the potential arbitrators from one to ten with one being
                  the most desirable. The arbitrator who receives the least
                  points shall be the arbitrator for such dispute. If there is a
                  tie, a random drawing will be held and the first arbitrator
                  chosen will be the arbitrator for the dispute. Judgment upon
                  the arbitration award will be final, binding and conclusive
                  and may be entered in any court having jurisdiction. The
                  parties hereto further agree that the arbitrator is not
                  authorised to award any punitive damages in connection with
                  any controversy or claim settled by arbitration hereunder.

27       COUNTERPARTS

         27.1     This Agreement may be executed in more than one counterpart,
                  each of which when executed and delivered shall be deemed to
                  constitute an original. This Agreement shall become effective
                  when one or more counterparts have been signed by both parties
                  and such a counterpart (so signed) has been delivered to each
                  of the parties.

IN WITNESS whereof this Agreement has been entered into the day and year first
above written.

SIGNED for and on behalf of
CIMA LABS INC

/s/ John M. Siebert

Name John M. Siebert

                                       44
<PAGE>
                                                                    EXHIBIT 10.1

Title President & CEO

Date August 23, 2001

SIGNED for and on behalf of
ASTRAZENECA UK LIMITED

/s/ C.R.W. Petty
C R W Petty
Authorised Signatory

Date 31 August 2001

                                       45
<PAGE>
                                                                    EXHIBIT 10.1

                                   SCHEDULE 1

                              PRODUCT SPECIFICATION

     [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
       WITH THE SECURITIES AND EXCHANGE COMMISSION; 4 pages omitted. ***]
<PAGE>
                                                                    EXHIBIT 10.1

                                   SCHEDULE 2

                       PACKING SPECIFICATION FOR UK AND US

     [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
       WITH THE SECURITIES AND EXCHANGE COMMISSION; 2 pages omitted. ***]
<PAGE>
                                                                    EXHIBIT 10.1

                                   SCHEDULE 3

                             STOCK REPORTING FORMAT

     [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
       WITH THE SECURITIES AND EXCHANGE COMMISSION; 3 pages omitted. ***]
<PAGE>
                                                                    EXHIBIT 10.1

                                   SCHEDULE 4

PRICE MATRIX [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***] MG TABLETS

CIMA TABLET PRICES

[***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION; 4 pages omitted. ***]
<PAGE>
                                                                    EXHIBIT 10.1

                                   SCHEDULE 6

                                SELF SUPPLY TERMS

1.       CIMA will grant to AstraZeneca an option to manufacture or have
         manufactured up to one hundred percent (100%) of its requirements of
         the Product for distribution, marketing and sale by AstraZeneca, its
         Affiliates and sublicensees ("Self-Supply") commencing at any time
         after the [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
         SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***] after
         commercial launch of the [***CONFIDENTIAL TREATMENT REQUESTED, PORTION
         OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
         COMMISSION.***] formulation of Product, except as provided in Section 2
         below. AstraZeneca may exercise such option by so notifying CIMA in
         writing at least three (3) months before AstraZeneca requires the
         Technology Transfer to begin that AstraZeneca intends to Self-Supply.
         If AstraZeneca exercises its option to Self-Supply, AstraZeneca shall
         pay an Option fee (the "Self-Supply Option Fee") equal to
         [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY
         WITH THE SECURITIES AND EXCHANGE COMMISSION.***]. For the avoidance of
         doubt, no further payments will be due from AstraZeneca to CIMA in
         respect of this option to Self-Supply any other (future or existing)
         dosage forms of the Product..

2.       If CIMA is unable to supply AstraZeneca with AstraZeneca's requirements
         of the Product, for any reason other than force majeure of a duration
         less than 60 days, (or AstraZeneca's inability to supply API as
         specified in Clause 7 of the Agreement) AstraZeneca may elect to
         manufacture the Product or have it manufactured by its Affiliates and
         sublicensees. In such situation, if AstraZeneca has already elected to
         Self-Supply at the time CIMA becomes unable to supply the balance of
         AstraZeneca's requirements, AstraZeneca will receive a refund of any
         portion of the
<PAGE>
                                                                    EXHIBIT 10.1

         Self-Supply Option Fee that AstraZeneca has paid to CIMA. However,
         AstraZeneca shall in such circumstances continue to be obligated to pay
         to CIMA the per tablet fee referred to in Section 3 below.

         If CIMA subsequently becomes able to again supply AstraZeneca with
         AstraZeneca's requirements of the Product and AstraZeneca elects to
         purchase any portion of its requirements of the Product from CIMA or
         elects to have CIMA reserve manufacturing capacity for manufacture of
         any portion of AstraZeneca's requirements of the Product, AstraZeneca
         shall repay to CIMA that portion of the Self-Supply Option fee refunded
         to AstraZeneca under this Section 2.

3.       If AstraZeneca elects to Self-Supply or to manufacture under Section 2
         of this Schedule, in addition to the technology transfer fee,
         AstraZeneca shall pay to CIMA either (i) [***CONFIDENTIAL TREATMENT
         REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
         EXCHANGE COMMISSION.***] per tablet manufactured by AstraZeneca, if at
         the time AstraZeneca elects to self-supply CIMA is supplying finished
         packaged Product to AstraZeneca, or (ii) [***CONFIDENTIAL TREATMENT
         REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
         EXCHANGE COMMISSION.***] per tablet manufactured by AstraZeneca, if at
         the time AstraZeneca elects to Self-Supply CIMA is supplying bulk,
         unpackaged blisters to AstraZeneca.

4.       If AstraZeneca elects to Self-Supply or to manufacture, under Section 2
         of this Schedule, AstraZeneca will have no right to make changes of any
         kind to the Product or the manufacturing process without CIMA's written
         consent, may not use of permit its Affiliates or sublicencees to use
         the technology for any purpose other

                                       2
<PAGE>
                                                                    EXHIBIT 10.1

         than to manufacture the Product, and may not permit its Affiliates or
         sublicensees to further transfer the technology. If AstraZeneca ceases
         to utilise the manufacturing technology to manufacture the Product, the
         manufacturing licence will automatically terminate and revert to CIMA.

5.       If AstraZeneca elects to Self-Supply or to manufacture under Section 2
         of this Schedule, CIMA will provide to AstraZeneca, its Affiliates
         and/or sublicensees, at AstraZeneca's sole expense, technical support
         and assistance to ensure the smooth and satisfactory establishment of
         the DuraSolv Technology at the new manufacturing site.

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]